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1. Introduction 
1.1 HMOs-Human milk oligosaccharides 
Human milk is considered to be the golden standard in infant nutrition. For many 
years, infant food companies have focused on strategies to imitate the composition of 
human milk with regard to protein classes, fatty acids and even various 
oligosaccharides. However, it has become obvious that the mere presence of a 
component in milk is not an indication for its biological activities. Therefore, today, the 
main focus is laid on the investigation of specific functions of individual milk 
components which is a prerequisite for the manufacturing of new products (Kunz et al. 
1996, Kunz et al., 2000).  
Human milk oligosaccharides (HMOs) are thought to be beneficial for the human 
milk fed infant because of their anti-inflammatory, anti-infective and immune 
stimulating properties (Kunz et al., 2000; Newburg et al., 2005; Sharon and Ofek, 
2000). The selective utilization of distinct HMOs as novel food ingredients, however, 
has been hampered mainly due to difficulties in obtaining or producing HMOs in larger 
amounts. Today, biotechnological tools are available or may be developed to produce 
sufficient amounts of individual components which can subsequently be investigated 
in functional studies. 
1.1.1 History 
As the golden standard for infant nutrition, human milk was studied by scientists 
and pediatricians for more than 100 years. Early at the end of 19th century, the infant’s 
survival rate were only about 70% to 80% in their first year, people already realized 
that, compared with the ‘bottle-fed’ infants, the breast-fed infants had lower mortality 
and lower chance for the diarrhea infections and also some other diseases (Bode, 
2012). 
In 1886, Escherich, the leading microbiologist in pediatrics from Austria, had 
described that the physiology of infants’ digestion had some relationship with the 
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intestinal microorganisms in infants’ body (Escherich, 1886). Later in about 1900, 
Moro had further observation to indicate that both breast-feeding and intestinal 
bacteria are important to infants’ health (Moro, 1990). In the same year, Tissier, from 
Paris, observed different fecal bacterial composition of breast-fed and bottle-fed 
infants (Tissier, 1990). Until then, people had first indicated that difference of bacterial 
composition in the infant’s intestine is linked to human milk composition. It was also 
the first description of microorganisms and their importance for infants’ health. But the 
specific components in human milk which affected the bacterial composition were still 
unknown. 
More than 40 years later, about 1930, Michel Polonowski and Albert Lespagnol in 
Lille, France, first characterized the unknown carbohydrate fraction from human milk 
and named it as ‘gynolactose’, which was only weakly soluble in methanol. They 
worked for several years and found that this gynolactose consisted of various 
components, such as hexosamines, which contains essential component nitrogen. 
(Polonowski and Lespagnol, 1929; Polonowski and Lespagnol, 1930; Polonowski and 
Lespagnol, 1931; Polonowski and Lespagnol, 1933). 
In 1954, Polonowski together with Montreuil introduced two-dimensional paper 
chromatography for the first time to separate the gynolactose into individual 
oligosaccharides, and identified the first two fucosyllactoses (2’-fucosyllactose and 
3-fucosyllactose) in the fraction that had been unknown at that time (Polonowski and 
Montreuil, 1954). In the same time, the chemist Richard Kuhn and the pediatrician 
Paul György, did several researches on the connection between bacteria and 
‘gynolactose’, and later proved that the ‘bifidus factor’ which was earlier reported by 
Schönfeld in 1926, contained oligosaccharides (Gauhe et al., 1954; György et al., 
1954a; György et al., 1954b; György et al., 1954c; Rose et al., 1954, Schönfeld, 
1926). 
In the following years, Jean Montreuil in France and Richard Kuhn in Germany 
both tried to describe the complex mixture in the ‘gynolactose’. They specified more 
than 12 individual HMO structures, such as 2’- fucosyllactose, 3-fucosyllactose and 
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difucosyllactose, lacto-N-tetraose, lacto-N-fucopentaose I and II, difucosyllactose, 
and so on (Montreuil, 1960; Kuhn and Baer, 1956; Kuhn et al., 1956, 1958, 1960; 
Kuhn and Gauhe, 1958, 1962). From about 1960s, Watkins investigated the blood 
group ABO and secretor system (Watkins, 1966). HMO, as the major components in 
human milk, contributed the structural characterization and blood group specificity. In 
1967, Grollmann confirmed that in milk samples of non-secretor women, 
2’-fucosyllactose can’t be detected (Grollman and Ginsburg, 1967; Grollman et al., 
1969, 1970). From 1967, Akira Kobata and Victor Ginsburg developed a new method 
to determine the three different oligosaccharides pattern using only a small amount of 
milk. They have been able to show fourteen oligosaccharides at the same time. Since 
then, more individual HMO fractions were separated and characterized (Kobata, 2010; 
Kobata and Ginsburg, 1969, 1972a, b; Kobata et al., 1969). 
Later in 1983, Heinz Egge, one of the leading pioneers in HMO field, was one of 
the first researchers to apply the fast atom bombardment mass spectrometry (MS) to 
characterize HMOs (Egge et al., 1983). Since then, a general method for mapping 
and sequencing of native and derivatized glycoconjugates was established.  
In recent years, scientists further studied on nutritional and biological properties 
of HMOs. An analytical method was developed to separate and characterize neutral 
and acidic lactose-derived oligosaccharides without prior derivatization or reduction 
by high-pH anion-exchange chromatography with pulsed amperometric detection 
(HPAEC-PAD) (Kunz et al., 1996a, b). There were also some researches on the 
biological functions of HMOs in both vivo study using 13C-labeling method and in vitro 
study using cell culture method (Bode et al., 2004a; Bode et al., 2004b; Gnoth et al., 
2000; Gnoth et al., 2001; Kuntz et al., 2009; Kuntz et al., 2008; Rudloff et al., 2006; 
Rudloff et al., 2012; Rudloff et al., 1996; Rudloff et al., 2002). 
1.1.2 Structures 
The core structure of human milk oligosaccharides contains three monomers: 
D-glucose (Glc), D-galactose (Gal), and N-acetylglucosamine (GlcNAc). With few 
exceptions, the lactose (Glc β1-4 Gal) is at the reducing end and the Gal residue 
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achieved an elongation with lacto-N-biose I (Gal β1-3 GlcNAc, LNB, type 1 chain) 
linked by β1-3 bond to the GlcNAc residue, or linked with N-acetyllactosamine (Gal 
β1- 4 GlcNAc, LacNAc, type 2 chain) by β1-3/6 bond to the GlcNAc residue. (Amano 
et al., 2009; Kobata, 2010). With the elongation, totally thirteen core structures have 
been classified. There are also two main monomers which can further more modify 
the conformation of HMO structures: L-fucose (Fuc) and sialic acid 
[N-acetylneuraminic acid (NeuAc)]. Fuc can have attachment to any position of the 
core structure via α1–2/3/4 linkages and NeuAc can linked with β 2–3/6 respectively. 
Among the structures, the type 1 chain plays a predominant role and is the unique 
feature of HMOs compared with other mammals or anthropoids milk oligosaccharides. 
Figure 1-1 shows the structures of HMOs. Table 1-1 lists the core structure and the 
basic HMO structures and their common abbreviations. 
 
 
 
 
                                         
 
 
 
 
 
Figure 1-1 Structures of HMOs. [According to Sela and Mills, 2010, Zivkovic and Barile, 
2011, with modifications] 
 
 
Table 1-1 Core structure and the basic HMO structures and their common abbreviations 
(According to Kunz et al., 2014, with modifications) 
Component Abbreviation Structure 
Lactose Lac Gal β1-4 Glc 
Lacto-N-biose I (type 1 chain) LNB Gal β1-3 GlcNAc 
N-acetyllactosamine 
(type 1 chain) 
LacNAc Gal β1-4 GlcNAc 
2’-Fucosyl-lactose 2’-FL Fuc α1-2 Gal β1-4 Glc 
3 -Fucosyl-lactose 3 -FL Gal β1-4 [Fuc α1-3] Glc 
Lacto-N-tetraose  LNT Gal β1-3 GlcNAc β1-3 Gal 
β1-4 Glc 
 

	-
 

 
 
Glucose 
GlcNAc 
NeuAc 
Fucose 
α1-4/3,α2-3/6,β1-3/4, β1-3/6 
\\\ 
 
α1-2/3,α2-6,β1-4 
Galactose 
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Lacto-N-neotretraose LNnT Gal β1-4 GlcNAc β1-3 Gal 
β1-4 Glc 
Lacto-difucosyl-tetraose LDFT Fuc α1-2 Gal β1-4 Glc [Fuc 
α1-3] 
Lacto-N-fucopentaose I LNFP I Fuc α1-2 Gal β1-3 GlcNAc 
β1-3 Gal β1-4 Glc 
Lacto-N-fucopentaose II LNFP II Gal β1-3 [Fuc α1-4] GlcNAc 
β1-3 Gal β1-4 Glc 
Lacto-N-fucopentaose III LNFP III Gal β1-4 [Fuc α1-3] GlcNAc 
β1-3 Gal β1-4 Glc 
Lacto-N-fucopentaose V LNFP V Gal β1-3 GlcNAc β1-3 Gal 
β1-4 [Fuc α1-3] Glc 
Lacto-N-difuco- 
hexaose I 
LNDFH I  Fuc α1-2 Gal β 1-3 [Fuc 
α1-4] GlcNAc β1-3 Gal β1-4 
Glc 
Lacto-N-difuco- 
hexaose II 
LNDFH II Gal β1-3 [Fuc α1-4] GlcNAc 
β1-3 Gal β 1-4 [Fuc α1-3] 
Glc 
3’-Sialyllactose 3’-SL NeuAc α2-3 Gal β1-4 Glc 
6’-Sialyllactose 6’-SL NeuAc α2-6 Gal β1-4 Glc 
Sialyl-lacto-N-tetraose a LST a NeuAc α2-3 Gal β1-3 
GlcNAc β1-3 Gal β1-4 Glc 
Sialyl-lacto-N-tetraose b LST b Gal β 1-3 [NeuAc α2-6] 
GlcNAc β1-3 Gal β1-4 Glc 
Sialyl-lacto-N-tetraose c LST c NeuAc α2-6 Gal β1-4 
GlcNAc β1-3 Gal β1-4 Glc 
Disialyl-lacto-N- 
tetraose 
DS-LNT NeuAc α2-3 Gal β1-3 
[NeuAc α2-6] GlcNAc β1-3 
Gal β1-4 Glc 
 
1.1.3 Lewis blood type and secretor specific components 
Until now, more than 100 HMOs have been identified and characterized (Kobata, 
2010). The structure of HMOs from individuals differs due to the secretor (Se) and 
Lewis (Le) genes of the mother. From the secretor difference, it is divided into two 
kinds: Se and non-Se. Individuals with a Se gene loci encoding α1-2- 
fucoslyltransferase (FUT2) are classified as Secretors (Se). FUT2 can facilitate the 
addition of Fuc to terminal Gal in an α1-2 linkage. Those who lack a functional FUT2 
enzyme are named as Non-secretors (non-Se). For the Lewis gene aspect, there are 
three different types: Le (a+b-), Le (a-b+) and Le (a-b-). Mothers who have an active 
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Le locus encoding α 1-3/4-fucosyltransferase (FUT3), are classified as Le positive. 
FUT3 can catalyzes the addition of Fuc to sub-terminal GlcNAc on type I chains in an 
α1-4 linkage. Individuals who can’t express FUT3 are called Le negative. Based on 
different Se and Le genes expression, HMOs can be divided into four groups: Se+Le+, 
Se+Le−, Se−Le+ and Se−Le−. Figure 1-2 shows the HMO fucosylation of the four 
groups. Table 1-2 concludes the Fucosyltransterase and the proportion of the four 
groups; Table1-3 lists some typical HMO structure and their existence in the type of 
milk groups (Kumazaki and Yoshida, 1984; Thurl et al., 2010; Viverge et al., 1990; Xu 
et al., 1996). 
 
 
Figure 1-2 Secretor and Lewis blood group dependent HMO fucosylation. HMO 
fucosylation highly depends on a woman’s Se and Le blood group status. If both FUT2 and 
FUT3 are expressed, milk contains HMO with Le b antigens. If only FUT3 is expressed, milk 
contains HMO with Le a antigens. If FUT3 is not expressed, HMOs contain neither Le a nor Le 
b antigens. (Bode, 2012) 
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Table 1-2 Fucosyltransferase and population of Lewis specific type (Kunz et al., 2014) 
Groups Type Fucosyltransferase % Population 
Se-Le+ Lewis a 
Nonsecretor 
α1-4 Fucosyltransferase 
(FUT3) 
20 
Se+Le+ Lewis b 
Secretor 
α1-2 Fucosyltransferase 
(FUT2) 
α1-4 Fucosyltransferase 
(FUT3) 
70 
Se+Le- Lewis a-b- 
Secretor 
α1-2 Fucosyltransferase 
(FUT2) 
~10 
Se-Le- Lewis a-b-  
Nonsecretor 
None ~10 
 
Table 1-3 Lewis blood group and secretor specific HMO (Kunz et al., 2014) 
Name 
 
Structure Le(a-b+) Le(a+b-) Le(a-b-) 
Secretor 
Le(a-b-) 
Non-secretor 
2’-FL Fuc α1-2 Gal β1-4 Glc + - + - 
LDFT Fuc α1-2 Gal β1-4 
Glc[Fuc α1-3] 
+ - + - 
LNFP I Fuc α1-2 Gal β1-3 GlcNAc 
β1-3 Gal β1-4 Glc 
+ - + - 
LNFP II Gal β1-3 [Fuc α1-4] 
GlcNAc β1-3 Gal β1-4 Glc 
+ + - - 
LNDFH II Gal β1-3 [Fuc α1-4] 
GlcNAc β1-3 Gal β 1-4 
[Fuc α1-3] Glc 
+ + - - 
 
1.1.4 Concentrations  
The concentration of HMOs varies widely during the lactation period decreasing 
from high amounts of up to 50 g / L in colostrum to about 10 – 15 g/L in mature milk 
(Kunz et al., 1999; Thurl et al., 2010; Urashima et al., 2012). The individual difference 
can mainly be explained by the genetic variance of the donors who have different 
blood group specific components as well as a distinguished set of milk 
oligosaccharides. 2/3 of all milk oligosaccharides are neutral species while 1/3 are 
acidic components which may also be fucosylated. The neutral oligosaccharide 
fractions show a very distinct pattern ranging from about 100 (Pattern A), 150 (Pattern 
B) to about 50 (Pattern C) components (Kunz, et al. 1996a).  
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It is intriguing to speculate whether these obvious differences have an impact on 
the infants’ health either immediately or in later life. This has not been investigated so 
far due to the difficulties to perform respective studies in humans.  
A human milk fed infant receives a large amount (about 8-12 g) of HMOs per day 
based on an average drinking volume of 850 ml per day (Kunz et al., 2000); including 
LNT, LNFP I and LNFP II, the uptake of which varies between 0.5 and 2 g per day 
(Rudloff et al., 2006). Thus, a large amount of individual HMOs passes the 
gastrointestinal tract of infants with each feeding (Kuntz et al., 2009; Kuntz et al., 
2008).  
1.1.5 Biosynthesis 
Many scientists and manufacturers have tried different methods to produce 
HMOs because of the potential effects of HMO on infant health. But until now, it is still 
difficulty to produce HMO in industry. 
HMO has lactose (Gal β1-4 Glc) at the reducing end, and is elongated by mainly 
LNB via β 1-3 linkage or LacNAc via β 1-3/6 linkage. So the essential of HMO 
biosynthesis is trying to extent the lactose biosynthesis (Intanon et al., 2014).  
The most attractive method is in vivo approach, which supposes microbial 
fermentation to express specific enzyme gene. In 2001, Dumon used E. coli as an 
engineering bacteria to over-express the α-1,3-fucosyltransferase from Helicobacter 
pylori, and produce various fucosylated HMO when lactose added to the medium 
(Dumon et al., 2001). Later in 2002, the group of Eric Samain tried to use a 
β-galactosidase-negative E.coli bacteria to over-express β-1, 3-N- acetylglucosaminyl 
-transferase gene from Neisseria meningitides (Priem et al., 2002). In a recent study, 
Guo utilized Pasteurella multocida sialyltransferase to produce both 3’-sialyl-lactose 
and 6’- sialyl-lactose (Guo et al., 2014).  
However, due to the complex mechanism of the HMO biosynthesis, many 
technique keys remain unknown and the produce of HMO still need to be further 
researched on. 
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1.2 Intestinal microorganisms in infants 
1.2.1 Intestinal microorganisms 
Since there is no oxygen in the gut lumen, the strictly aerobic bacteria can’t grow 
in the gut. The main types of intestinal microorganisms are strictly anaerobic bacteria 
and a small amount of facultative anaerobic bacteria. The facultative bacteria can 
perform either aerobic or anaerobic metabolism, such as E. coli, Lactobacilli, 
Enterobacter, Streptococci and Staphylococci, the strictly anaerobic bacteria can’t 
utilize oxygen and lack the enzymes that detoxify oxygen, such as Bifidobacteria, 
Bacteroides and Clostridium (Hayashi et al., 2002). Because of the growth condition 
of strictly anaerobic bacteria, even the air contact is minimized during the cultivation, 
there were still about half populations of bacteria that can’t be cultivated. Among the 
not yet cultivated bacteria, about 70% are novel (Eckburg et al., 2005). 
1.2.2. Intestinal microorganisms in infants 
1.2.2.1 Culture-based studies on bacteria in infants 
Early in 1971, Mata and Urrutia studied the colonization of intestinal 
microorganisms in breast-fed infants. Later in 1980s, Rotimi and his research group 
researched on the bacterial flora in healthy neonates; Stark, Yoshioka and Benno 
compared the composition of intestinal microorganisms from breast-fed and 
formula-fed infants during their first year (Mata and Urrutia, 1971; Benno et al., 1984; 
Rotimi and Duerden, 1981; Stark and Lee, 1982; Yoshioka et al., 1983). 
In 2008, Adlerberth summarized the facultative and anaerobic bacteria in infant 
within one week and 3 to 5 weeks, as well as the bacteria in adults. They included the 
colonization frequency and the mean log counts for the bacteria groups (Adlerberth 
and Wold, 2009). Table 1-4 summarized the gut bacteria in culture-based studies. 
The data from adults are for comparison. 
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Table 1-4 Colonization frequency (given in %) and mean log counts for various groups of gut 
bacteria in culture-based studies (Adlerberth and Wold, 2009) 
 1week 
(%) 
 
Counts in 
colonized 
(10log) 
3-5weeks 
(%) 
 
Counts in 
colonized 
(10log) 
Adults 
(%) 
 
Counts in 
colonized 
(10log) 
Facultative 
bacteria 
      
Enterobacteria 87 6.2-9.4 99 6.1-9.6 98 8.7 
  E. coli 74 7.9-9.7 82 7.8-9.4 93 8.6 
Other 
enterobacteria 
16 8.7-10.0 42 7.7-8.7   
Enterococci 92 5.7-9.0 87 4.5-9.6   
  E. faecalis   81 6.3-8.7 80 7.5 
  E. faecium   23 5.7-8.8 31 7.4 
Staphylococci 49 5.0-5.1 60 4.7-10.1   
  S. aureus 5 4.9-5.0 19 4.6-5.0 11 5.4 
  Coagulase 
-negative 
21 7.0 48 5.2-5.9           31 7.4 
Anaerobic 
bacteria 
      
  Bacteroides 55 4.8-9.3 64 6.0-10.1 99 11.3 
  Veillonella 52  56 6.3-8.7 34 8.5 
Bifidbacteria 77 6.2-10.2 69 4.3-11.3 74 10.2 
Clostridia 51 3.1-7.2 60 3.0-8.1 100 9.8 
Lactobacilli 35 4.4-7.0 35 5.0-9.1 78 9.6 
Eubacterium 23 6.0-6.6 12 6.1-9.7 94 10.7 
Gram-positive 
cocci 
21 10.7 13 5.7-11.1 94 10.6 
 
In Table 1-4, the proportion (%) of infants containing a particular group of bacteria 
and the faecal population counts in colonized infants (log CFU/g faeces) were given. 
Data were adapted and summarized from 18 references and the range indicated 
highest and lowest mean counts in the available studies. Data of adults were adapted 
from Finegold (1983), who reporting from 141 individuals. Counts in this study were 
calculated from dry faecal matter, which gives approximately one log unit higher 
values than counts per gram faeces (Adlerberth and Wold, 2009). 
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1.2.2.2 Factors influencing bacterial colonization pattern 
The bacteria colonization may depend on the delivery mode (vaginal versus 
cesarean section) or feeding pattern. According to former studies, E. coli colonization 
in neonates was partly originated from the maternal faecal flora. Klebsiella, 
Enterobacteria, Enterococci, C. difficile and Bifidobacteria may spread between 
infants. For Bifidobacteria, the identified types have been found in both maternal and 
infant faecal microorganisms (Adlerberth et al., 1999; Adlerberth et al., 1998; 
Bettelheim and Lennox-King, 1976; Fryklund et al., 1992; Martirosian et al., 1995; 
Mitsuoka and Kaneuchi, 1977; Persson et al., 1986; Singh et al., 2005; Tannock et al., 
1990; Cheng et al., 2013; Neu and Rushing, 2011; Putignani et al., 2014; Salminen et 
al., 2004). 
The delivery mode is an important factor that influences the colonization pattern. 
There are two kinds of delivery mode, vaginal birth or caesarean section. Infant born 
by normal vaginal birth can contact with their mother’s gut and vagina, so that they 
can acquire their mother’s intestinal and vaginal microorganisms, such as Bacteroides, 
Bifidobacteria and E. coli. In contrast, infant born by caesarean section don’t have the 
chance to contact their mother’s intestinal and vaginal microorganisms and they 
couldn’t acquire the Bacteroides and Bifidobacteria at the beginning (Adlerberth et al., 
1991; Adlerberth et al., 2006; Adlerberth et al., 2007; Hall et al., 1990; Penders et al., 
2006; Neu and Rushing, 2011; Salminen et al., 2004; Putignani et al., 2014). Due to 
the reduced competition with Bacteroides and Bifidobacteria, the amount of other 
Enterobacteriaceae, such as Klebsiella, Enterobacter and Clostridia can increase. 
The feeding pattern is another factor influencing the colonization pattern. Breast 
milk may contain kinds of bacteria. Martin et al. found that human milk is a source of 
lactic acid bacteria, such as Lactobacillus gasseri and Enterococcus faecium (Martin 
et al., 2003). Kawada et al. investigated the transmission of Staphylococcus aureus 
between infants and their mothers through breast-feeding (Kawada et al., 2003). It 
was thought that the feeding pattern influences the gut microorganisms and the 
breast-fed and bottle-fed infants would be different from the bacteria colonization 
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pattern. But recently, the formulas are more similar to breast milk, so that the 
differences of the gut bacteria between breast-feeding and formula-feeding infants are 
smaller. Table 1-5 summarized comparison the amount of gut bacteria of breastfed 
and formula fed infants before and after 1980 (Adlerberth and Wold, 2009). 
 
Table 1-5 Results of studies comparing the gut bacteria of breast-fed and formula-fed 
infants before and after 1980 (According to Adlerberth and Wold, 2009). Numbers of positive 
results/total examinations are given. 
 Number of studies 
Bacterial Groups More in breastfed No clear difference Less in breastfed 
 Before 
1980 
After 
1980 
Before 
1980 
After 
1980 
Before 
1980 
After 
1980 
Bifidobacteria 5/6 7/27 1/6 20/27 0/6 0/27 
Bacteroides 0/3 2/19 1/3 9/19 2/3 8/19 
Clostridia 0/3 0/17 0/3 4/17 3/3 13/17 
Lactobacilli NT 2/16 NT 10/16 NT 4/16 
Enterobacteriaceae 0/7 1/21 5/7 9/21 2/7 11/21 
Enteroccocci 0/2 0/16 0/2 5/16 2/2 11/16 
Staphylococci NT 5/12 NT 7/12 NT 0/12 
Note: NT means not tested. 
 
From Table 1-5, the following points can be gathered. The results of 
Bifidobacteria before 1980 showed that the number was higher in breast-fed infant. 
After 1980, with the development of formula milk, most studies had no clear difference 
between breast-fed and formula-fed infants. No study showed less Bifidobacteria in 
breast-fed infants. For Bacteroides and Clostridia, Enterobacteriaceae and 
Enteroccocci, nearly no study indicated more bacteria in breast-fed infants. Data from 
Staphylococci revealed more bacteria in breastfed infants or no clear difference. Most 
studies of Lactobacilli found no difference in breast-fed or bottle-fed infants, and some 
studies actually report less Lactobacilli in breast infants. However, L. rhamnosus was 
observed more common in breast-fed infant, indicating that this particular species 
may be favored by breast-feeding (Adlerberth and Wold, 2009; Ahrne et al., 2005). 
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1.3 Function of HMOs and influence on intestinal 
microorganisms 
1.3 1 Biological functions of HMOs 
1.3.1.1 Prebiotics effects 
Many researches have indicated that HMOs showed the prebiotic effects 
because the interactions between HMOs and the infants’ intestinal microbiota. In 
1954, György et al. found that the probiotics, variant of Lactobacillus bifidus (later 
named as Bifidobacterium bifidum), need a special growth factor from human milk 
(György et al., 1954c). But they didn’t know which components were the growth 
factors. The growth factor was later proved to be HMOs by the following series of 
studies. In recent time, more studies focused on the interactions between HMOs and 
growth of probiotics. In 2007, LoCascio et al. researched on the glycol-profiling of the 
specific gut bacteria Bifidobacterium longum biovar infantis, and found that the 
bacteria has preferential consumption of certain short-chain HMOs secreted in early 
human lactation because it can express the enzymes to cleave the intact HMOs 
(LoCascio et al., 2007). The Prebiotic effects of HMOs are shown in Figure 1-3 (Bode, 
2009).  
 
Figure 1-3 Prebiotic effects of HMOs. This simplified scheme shows that desired (green) 
and undesired (blue) bacteria have different capabilities of metabolizing HMOs. In the 
presence of HMOs (right), the desired bacteria metabolize HMOs and thrive while undesired 
bacteria cannot metabolize HMOs. In the absence of HMOs (left), both bacteria can grow. 
(According to Bode 2009) 
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1.3.1.2 Anti-adhesive and glycome-modifying effects 
Most bacteria, both in commensals or pathogens format, can express 
glycan-binding proteins, which are named as lectins. Through lectins, the bacteria can 
bind to oligosaccharides on the host’s epithelial cell surface. This ability can reveal the 
virulence of most bacteria, such as Campylobacter jejuni, E. coli, Vibrio cholera and 
Salmonella bacteria. The glycan-binding sometimes is determined by HMOs, because 
HMOs are structurally similar to some of the glycans binding to the intestinal epithelial 
cell surface. That means the HMOs can serve as soluble bacterial lectin ligand 
analogs, and can block the bacterial attachment. HMOs can also alter the 
glycan-related gene expression, modify the intestinal epithelial glycosylation 
machinery, therefore, the cell-surface glycome is changed and the bacteria has a 
barrier to attach, proliferate and colonize. Figure 1-4 shows the anti-adhesive and 
glycome-modifying effects of HMOs. 
 
Figure 1-4 Anti-adhesive and glycome-modifying effects of HMOs. Most bacteria express 
glycan-binding proteins (lectins), that bind to glycans on the host’s epithelial cell surface (A), 
which is essential for bacteria to attach (a) and to colonize the intestine (b). Some pathogens 
invade into the host (c). HMOs are structurally similar to glycans and can serve as bacterial 
lectin ligand analogs and block bacterial attachment (B). Human milk oligosaccharides (HMO) 
may also modify the cell-surface glycome (glycocalyx) to impact bacterial attachment(C). 
(According to Bode 2009) 
 
1.3.1.3 Systemic effects 
Besides local functions, HMOs also may have some effects on systemic 
infectious, inflammatory and immune processes. First, in the immune system, HMO 
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can modify the protein-carbohydrate interactions through selectins, which have 
effects on the cell-cell interactions. E-selectin can adjust leukocyte deceleration 
(rolling) on endothelia cells, while P-selectin has effects on leukocyte and also helps 
the formation of platelet-neutrophil complexes (PNC). Some fucosylated and 
sialylated HMOs can resemble the binding determinants, like glycoconjugate ligands. 
The sialylated HMOs are found to have functions of reducing rolling on activated 
endothelial cells. Some complex HMOs can enhance the selectin-ligand binding; 
some can also inhibit the formation of PNC (Bode et al., 2004a; Bode et al., 2004b; 
Ley, 2003; Maaheimo et al., 1995; Peters et al., 1999; Rudloff et al., 2002; Springer, 
1994; Varki, 1997). 
Based on these immunmodulatory effects, HMOs may be beneficial to breast-fed 
infants’ immune system. For example, human milk can reduce the incidence for 
necrotizing enterocolitis (NEC) and other inflammatory diseases, the effective 
components in human milk were considered to be HMOs, but still to be proof (Bode et 
al., 2004a; Bode et al., 2004b; Maaheimo et al., 1995; Rudloff et al., 2002). 
Second, HMOs also have some effects on immune system relating T-cells. The 
sialylated HMOs have influence on lymphocyte maturation and cord blood T-cells; it 
can increase the number of INFγ-producing CD3+CD4+ and CD3+CD8+ lymphocytes, 
IL13-producing CD3+CD8+ lymphocytes. In addition, some single HMO standard can 
also influence the peritoneal macrophages. For example, LNFP III and LNnT can 
inhibit naïve CD4+Tcell responses, and LNFP III itself can stimulate macrophage 
activity in vitro and can have benefit to the secretion of prostaglandin E2, IL-10 and 
TNF α (Atochina et al., 2001; Atochina and Harn, 2005).  
Third, HMOs may have effects on the brain glycoconjugate composition and 
functions. Early around 1980, researchers (Carlson and House, 1986; Witt et al., 1979) 
studied the rat brain and found that Sialic acid and sialyllactose (SL) have an 
influence on brain sialic acid composition.  
Introduction 
 
16 
 
1.3.2 Influence on epithelial cells and intestinal microorganisms 
The intestinal colonization with balanced microorganisms is important for immune 
system (Kau et al., 2011). There is an intensive interaction between intestinal 
microorganisms and immune system and the diversity and stability of gut microbiota is 
always important for health (Lozupone et al., 2012; Maynard et al., 2012). It has been 
known for a long time that HMOs has an important role on the intestinal colonization, 
but the specific functions were to be investigated. For many years, many researchers 
studied the functions of HMOs or the specific single HMO component on the epithelial 
cells or intestinal microorganisms. 
Early in the 1950s, György found that oligosaccharides have effects on the 
growth of Bifidobacterium bifidum subsp. Pensylvancium that was isolated from infant 
faeces (György et al., 1954c). This discovery leaded to a topic of research on the 
effects of oligosaccharides to the infant gut bacteria. In the next years, with the 
development of technology, scientists researched on the relationship between HMOs 
and intestinal cells or microorganisms in many aspects by different ways: in animals, 
in vitro and in humans. Until now, this topic is still of great scientific interest. In former 
studies, the research factor were HMO fractions or specific HMOs, such as neutral 
HMOs, Sialylated HMO, fucosylated HMO, or single HMO standard, such as 2’-FL, 
LNT, LNnT, 3’-SL and DS-LNT. Some studies were also about the HMO related 
monosaccharide, such as sialic acid, Fuc, Gal, Glc and GlcNAc, these components 
were also important for the study or comparison of HMOs. The investigations were 
with gut microbiota or cell culture lines (Coppa et al., 2006; Jantscher-Krenn et al., 
2012a; Asakuma et al., 2011; Angeloni et al., 2005). The microorganisms were mainly 
Bifidobacteria in several subspecies, among which B. infantis was the most important 
in the early stage of infant. L. acidophilus, L. lactis, E. coli, Staphylococcus, Bacillus, 
Streptococcus and Bacteroides were also the studies because they were the 
important bacteria in infants’ gut. For cell cultures, Caco-2 cells, HT-29 cells, Cord 
blood T cells were used for study. These studies found that HMOs influence intestinal 
microorganisms through the prebiotic effects and some kinds of intestinal 
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microorganisms can grow with HMOs as sole carbon substrates (Hunt et al., 2012; 
LoCascio et al., 2007; Marcobal et al., 2010). And the effects on intestinal cell lines 
were as follows: Inhibition of adhesion of undesired bacteria; reduction of proliferation; 
alteration of cell dynamics; induction of differentiation and influence on apoptosis, and 
so on (Kuntz et al., 2009; Kuntz et al., 2008). Table 1-6 summarized the functions 
studies with single HMO and HMO fractions, the studies were performed in vitro, 
animals or humans.  
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Table 1-6 Examples for effect studies with single HMO and HMO fractions in vitro, animals or humans (According to Kunz et al., 2014, with 
modifications) 
 Effect Factor Investigated in/with Reference 
Prebiotic effects; influence on different 
Bifdobacteria; description of special HMO 
using pathways 
Neutral HMO B. infantis; 
B. bifidum, B. breve;  
B. longum 
(Asakuma et al., 2011; Garrido et 
al., 2012; Kitaoka, 2012; Sela et al., 
2008; Yoshida et al., 2012) 
Inhibition of adhesion of E.coli, Vibrio 
cholerae, and Salmonella fyris to Caco-2 cells 
HMO Caco-2 cells (Coppa et al., 2006) 
Reduction of Entamoeba attachment and 
cytotoxicity 
HMO with terminal 
Gal (e.g. LNT) 
HT-29 cells (Jantscher-Krenn et al., 2012a) 
Increase in INFγ-, IL-13-producing T cells Sialylated HMO Cord blood T cells (Eiwegger et al., 2004) 
Influence on rolling and adhesion of 
human leukocytes 
Sialylated and 
fucosylated HMO 
High umbilical vein 
endothelial cells 
(Bode et al., 2004a) 
Reduction of platelet neutrophil complex 
formation and neutrophile activation 
Sialylated and 
fucosylated HMO 
Ex vivo model with fresh 
human blood 
(Bode et al., 2004b) 
Changes in cell surface glycosylation 
EPEC adhesion reduced 
3’-SL Human intestinal cell 
lines, gene expression 
(Angeloni et al., 2005) 
Influence on brain sialic acid 
content 
Sialic acid, 
sialyllactose 
Rats (Carlson and House, 1986; Wang, 
2009; Witt et al., 1979) 
Cure of H. pylori infections (50%)  3’-SL Rhesus monkeys  (Mysore et al., 1999) 
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Effects depend on cell lines; inhibition/ 
reduction of proliferation; alteration of cell 
dynamics; induction of differentiation and/or 
influence on apoptosis 
Neutral/sialylated 
HMO fraction or 
single HMO 
Transformed and 
nontransformed intestinal cell 
lines (HT 29, Caco 2, HIEC) 
(Kuntz et al., 2009; Kuntz et al., 
2008) 
Reduction of S. pneumoniae and H. influenzae 
adhesion 
LNnT and 
sialylated LNnT 
Rats (IdanpaanHeikkila et al., 1997) 
Microbial composition influenced 
DSS-induced colitis reduced 
3’-SL Sialyltransferase-deficient mice (Fuhrer et al., 2010; Weiss and 
Hennet, 2012) 
Necrotizing enterocolitis reduced DS-LNT Rats (Jantscher-Krenn et al., 2012b) 
HMO consumption by Bacteroides via mucus 
utilizing pathways 
HMO, LNnT,  Gnotobiotic mice (Marcobal et al., 2011) 
Effects on SCFA and microbial modulation HMO, LNnT Pigs (Li et al., 2012) 
No reduction of colonization of throat 
and nasopharynx with S. pneumonia 
or H. pylori; tendency of reduced ‘abnormal’ 
ears 
LNnT 
supplemented 
formula 
Infants (Prieto, 2005) 
No effects in acute otitis media LNnT Infants (placebo- controlled 
trial) 
(Ukkonen et al., 2000) 
Reduction of diarrhea (e.g. 
Campylobacter diarrhea)  
Association with 
total fucosylated 
oligosaccharides 
and 2’-FL in milk 
Infants (Morrow et al., 2004; Ruiz-Palacios 
et al., 2003)  
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Association with Crohn’s disease Nonsecretor status Genotyping in young and adult 
individuals 
(McGovern et al., 2010) 
Association with mortality, gram negative 
sepsis and necrotizing enterocolitis 
Low or nonsecretor 
status 
Preterm infants; secretor 
genotyping/ phenotyping 
(Morrow et al., 2011) 
Consumption of HMOs by gut-related 
microorganisms 
HMO Enterococcus, E. coli, 
Streptococcus, B. infantis,  
Bacteroides, Clostridium,   
L. lactis, L. acidophilus 
(Marcobal et al., 2010) 
Human milk glycomics and gut microbial 
genomics showed a correlation between HMO 
and gut microbiota 
HMO Staphylococcus, Bacillus, 
Streptococcus, Bacteroides 
Bifidobacteria, et al.  
(De Leoz et al., 2015) 
Metabolism of Sialic acid by microbiota Sialic acid C. sakazakii (Joseph et al., 2013) 
Consumption of HMOs by infant-gut 
associated Bifidobacteria 
HMOs, Fuc, Gal, 
Glc, GlcNAc and 
single HMO 
B. infantis, B. bifidum,  
B. breve, B. longum 
(LoCascio et al., 2007) 
(Asakuma et al., 2011) 
Molecular linkages between Bifidobacteria 
and HMOs 
HMOs B. infantis (Sela and Mills, 2010) 
HMOs promote the growth of gut microbiota HMOs Staphylococcus epidermidis 
Staphylococcus aureus 
(Hunt et al., 2012) 
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2.#Objective#
In former studies, the major research focus was on effects of the whole HMO 
fractions on intestinal microorganisms. So far, the influence of HMO fractions with 
specific Lewis blood type or differences between neutral and acidic HMO fractions 
has not been investigated yet.  
The overall aim of this dissertation was to investigate the effects of HMOs on the 
growth of intestinal microorganisms. HMO fractions were isolated from human milk 
samples with known specific Lewis blood type (Lewis a, Lewis b and Lewis negative). 
The whole HMO fractions were separated into neutral and acidic fractions. We also 
used five single HMO standards for the microorganisms study, such as 2’-FL, 3-FL, 
LNT, LNnT and 6’-SL. To evaluate the results from HMOs, mono- and di- saccharides 
were used for the experiments (glucose, galactose and lactose), which are also an 
important carbon substrate for microorganisms’. According to previous studies and 
the existence of intestinal microorganisms in infants’ gut, we selected seven kinds of 
microorganisms for the study: Lactococcus lactis subsp. lactis, Lactobacillus 
acidophilus, Bifidobacterium longum subsp. infantis, Bifidobacterium longum subsp. 
longum, Bacteroides vulgatus, Cronobacter sakazakii, Akkermansia muciniphila. The 
growth conditions for the microorganisms will be optimized using glucose as the sole 
carbon substrate. Then the glucose will be replaced by galactose, lactose, neutral and 
acidic HMO fractions, or single HMO standards. The growth curves will be used to 
determine growth, the carbon substrates in the medium will be labeled using 2-AA 
and analyzed by RP-HPLC, and the metabolic products will be analyzed by HPLC 
(analysis for fatty acid detection).  
Different methods will be applied: 
• to obtain growth curves after the application of various substrates to the 
culture medium; 
• to determine utilized carbon substrates in the medium after labeling with 2-AA 
followed by RP-HPLC analysis;  
• to analyze different metabolic products, such as various fatty acids. 
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3. Materials and methods 
3.1 Materials 
3.1.1 General laboratory equipment 
Table 3-1 List of the general laboratory equipment and accessories 
Equipment Type Company 
Autoclave  Sanoclav 
Centrifuge Universal 32R Hettich 
Conical flask  Schott Duran 
Deck glass 18*18 mm Roth 
Electronic Balance BP4100S Sartorius 
Electronic Balance R300S Sartorius 
Electronic Balance SPD51 SCALTEC 
Filter 0.45 µm, 25 mm Macherey Nagel 
Filter paper 0.45 µm 47 mm, PC55 Schleicher&Schuell 
Filter paper 0.2 µm, 47 mm, RC58 Whatman 
Incubator  WTC Binder 
Injector 5 ml BIBraun 
Laboratory film 4IN*125FT Parafilm 
Lyophiliser Christ ALPHA 1-4 SciQuip 
Magnetic stirrer MR3001 Heidolph 
Measuring cylinder  Hirschmann EM Techcolor 
Menzel Glass  Thermo Scientific 
Microscope Axiophot 2 ZEISS 
Nitrogen generator  Whatman 
Pump Aircraft Type ZS 50 ARC Hydro-Vacuum Aircraft 
Pipet  Eppendorf 
Pipet  Gilson Pipetman 
Pipette  Assistant 
PH meter  inoLab 
Pump P-500 Pharmacia 
Pump S1.5 Siemens 
Refrigerator  Bosch, Liebherr, Siemens 
Refrigerator Minus 80 Nunc 
Respirator 50 BE-EM Visama Plus BIBraun MAGV 
Laborbedarf 
Rotary evaporator   Buechi 
Screw cap 1.0 mm 45S chm 
Select Plus  Unigloves 
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Spectrophotometer Mode: GENESYS 10UV ThermoSpectronic 
Speed-Vac plus SC100A Savant 
Vapornet VN100 Savant 
Stirrer MR3001 Heidolph 
Syringe filter 0.45 µm, 4 mm, Cellulose 
Acetate Membrane 
Nalgene 
Volumetric flask  Hirschmann EM Techcolor 
Vortex mixer M10 REAX top Heidolph 
 
3.1.2 Equipment for Chromatography 
Table 3-2 List of Chromatography and accessories used in the study 
Equipment Type Company 
Dionex System DP ICS-5000 Thermo Fisher Scientific 
Dionex Autosampler AS-AP dual channel Thermo Fisher Scientific 
Dionex Column Carbopac PA-1 column 
(4 mm×250 mm) 
Thermo Fisher Scientific 
Dionex Column Carbopac PA-1 guard 
column (2 mm × 50 mm) 
Thermo Fisher Scientific 
Dionex Column Syncronis C18 column (250 
×4.6, 10 mm guard 
Thermo Fisher Scientific 
HPLC  Shimadzu 
HPLC Column RESOURECE Q; 6 ml Amersham 
HPLC Column Oven CTO-10AC Shimadzu 
HPLC detector  SPD-10A Shimadzu 
HPLC fraction 
collector 
FRC-10A Shimadzu 
HPLC pump LC-10AS Shimadzu 
HPLC Solvent 
Delivery System 
S1000 Sykam 
MALDI target plate AnchorChip TM 600 Bruker Daltonics 
Mass spectra  Ultitraflex I instrument Bruker Daltonics 
Sephadex G25 TM 26/10 Desalting HiPrep 
Fraction collector Frac-920 HiPrep 
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3.1.3 Reagents 
Table 3-3 List of general information of reagents used in the study 
Reagents Chemical 
formula 
Company Molecular 
weight 
Purity 
2-Aminobenzoic 
acid (2-AA) 
    
6-aza-2- thiothymine 
(ATT) 
 Sigma Aldrich   
Acetic acid, 
Rotipuran 
C2H4O2 Roth  60.05 100% 
Acetonitrile (ACN) 
Chromasolv Plus 
C2H3N Sigma-Aldrich 41.05  99.9%  
Ammonium acetate  C2H7NO2 Fluka 77.18  98.0% 
Ammonium acetate  C2H7NO2 Roth 77.08 99% 
Ammonium acetate  CH3COONH4 Merck 77.08  98% 
Bacto Peptone   BD   
Bacto Casitone  BD   
BBL Trypticase Soy   BD   
Brain Heart Infusion 
Broth  
 Fluka   
Caseinpeptone, 
Tryptone 
 OXOID   
Calcium 
chloride-2-hydrate 
CaCl2·2H2O Riedel-deHaeen 147.02 99% 
D (-)-Fructose  C6H12O6 Merck 180.16   
D (+)-Galactose  C6H12O6 Merck 180.16  
D (+)-Glucose  C6H12O6 Roth 180.16   
D (+)-Glucose  C6H12O6 Sigma 180.16   
D (+)-Lactose  C12H22O11·H2O  Riedel-deHaeen 360.32   
Di-Ammonium 
hydrogen citrate  
C6H14N2O7 Merck 226.19   
Difco Agar, 
Granulated  
 BD   
Dimethyl sulphoxide 
(DMSO) 
C2H6OS Sigma 78.13   
Di- Potassium 
hydrogen phosphate  
K2HPO4 Merck 174.18  
Ethanol C2H6O AppliChem 46.07 99.2% 
Isomaltotriose, DP3 
Supelco 
    
Lactose milk sugar, 
Monohydrate  
C12H22O11 H2O  Sigma 360.3   
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L-cysteine 
hydrochloride 
Monohydrate 
L-cysteine-HCl· 
H2O 
Sigma-Aldrich 175.63 98% 
Magnesium 
Sulphate 
heptahydrate  
MgSO4·7H2O  Roth 246.48  99% 
Manganese-sulfate 
monohydrate  
MnSO4·H2O Roth 169.02 99% 
Meat Extract   Fluka   
Potassium chloride  KCl Roth 74.56  99.5%  
Potassium 
dihydrogen 
phosphate  
KH2PO4 Roth 136.09  99% 
Resazurin  Roth   
Sodium Acetate C2H3NaO2 Roth 82.03  
Sodium chloride  NaCl Roth 58.44  
Sodium hydroxide NaOH Riedel-deHaeen 40.00 98.5% 
Sodium hydrogen 
carbonate 
NaHCO3 Fluka 84.01 99.7% 
Sodium citrate 
tribasic dehydrate  
C6H5NaO7 2H2O  Sigma-Aldrich  294.10  99.0% 
Sodium 
cyanoborohydride  
CH3BNNa Sigma-Aldrich  95% 
Sodium dihydrogen 
phosphate  
NaH2PO4 2H2O  Merck 156.01  98% 
Sodium sulfate  Na2SO3 Merck 126.04  96% 
Soluble Starch  (C6H10O5)n  Roth (162.14)n   
Tween 80  Merck   
Water, Rotisolv Ultra 
LC-MS  
H2O Roth   
Water, Aqua ad 
iniectabilia  
H2O Baxter   
Yeast Extract   Merck   
 
3.1.4 HMO fractions and standard 
    Neutral and acidic HMO fractions were isolated from human milk samples with 
known Lewis specific blood type modified according to Kunz et al. 1996 (Kunz et al., 
1996a).  
Human milk samples were from six mothers who were at the first weeks of 
lactation. Among the six human milk samples, three samples were from mothers with 
Lewis a blood type, labeled as: LeA1, LeA2 and LeA3; two samples were from mothers 
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with Lewis b blood type, labeled as LeB1and LeB2; one sample was from mother with 
Lewis negative blood type, labeled as Le0. 
HMO single standards used in the study were as follows: 2´-FL, 3-FL, LNT, LNnT, 
6´-SL were from Glycom (Copenhagen, Denmark), LDFT and LNFP V were from 
Elicityl (Crolles, France), LNFP I, LNFP II, LNFP III, LNDFH I, LNDFH II were from 
Dextra laboratories (West Berkshire, United Kingdom). 
 
3.1.5 Microorganisms 
Table 3-4 General information of bacteria, including their source and medium for 
cultivation 
Name of bacteria Abbreviation Bacteria No. Medium 
Lactococcus lactis 
subsp. lactis 
L. lactis DSMZ 20481 MRS medium 
Lactobacillus 
acidophilus 
L. acidophilus DSMZ 20079 MRS medium 
Bifidobacterium 
longum subsp. 
infantis 
B. infantis DSMZ 20088 Bifidobacterium 
medium  
Bifidobacterium 
longum subsp. 
longum 
B. longum DSMZ 20219 Bifidobacterium 
medium 
Bacteroides vulgatus B. vulgatus DSMZ 1447 Modified Reinforced 
Clostridial Broth 
Cronobacter 
sakazakii 
C. sakazakii DSMZ 4485 MRS medium 
Akkermansia 
muciniphila 
A. muciniphila DSMZ 22959 Modified Reinforced 
Clostridial Broth 
3.1.6 Mediums 
MRS medium (g/L): 
Casein peptone (tryptic digest) 10, Meat extracts 10, Yeast extracts 5, Glucose 20, 
Tween80 1, K2HPO4 2, Na-acetate 5, (NH4)2citrate 2, MgSO4·7H2O 0.2, MnSO4·H2O 
0.05. 
 
MRS medium with L-cysteine (g/L): 
Casein peptone (tryptic digest) 10, Meat extracts 10, Yeast extracts 5, Glucose 20, 
Tween80 1, K2HPO4 2, Na-acetate 5, (NH4)2citrate 2, MgSO4·7H2O 0.2, MnSO4·H2O 
0.05, L-cysteine-HCl·H2O 2. 
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Bifidobacterium medium:  
Casein peptone (tryptic digest) 10.00 g, Yeast extract 5.00 g, Meat extract 5.00 g, 
Bacto Soytone 5.00 g, Glucose 10.00 g, K2HPO4 2.00 g, MgSO4·7H2O 0.20 g, 
MnSO4·H2O 0.05 g, Tween80 1 ml, NaCl 5.00 g, L-cysteine-HCl·H2O 0.50 g, salt 
solution (see below) 40.00 ml, Resazurin (25 mg/100 ml) 4.00 ml, distilled water 
950.00 ml. pH 6.8. 
Salt solution: CaCl2·2 H2O 0.25 g, MgSO4·7H2O 0.50 g, K2HPO4 1.00 g, KH2PO4 1.00 g, 
NaHCO3 10.00 g, NaCl 2.00 g, distilled water 1000.00 ml. 
 
Modified Reinforced Clostridial Broth: 
Peptone 10.0 g, Meat Extract 10.0 g, Yeast Extract 3.0 g, Glucose 5.0 g, NaCl 5.0 g 
Soluble Starch 1.0 g, L-cysteine-HCl 0.5 g, Sodium Acetate 3.0 g, Resazurin (0.025%) 
4.0 ml, distilled water 1000.0 ml. pH 6.8. 
3.2 Methods 
3.2.1 Isolation and separation of HMO fractions 
 
Figure 3-1 Isolation of neutral and acidic HMO fractions from human milk with known 
Lewis specificity (Lewis a, Lewis b and Lewis negative) (Kunz et al., 1996a).  
 
As shown in Figure 3-1, neutral and acidic HMO fractions were isolated from 
human milk samples step by step. Human milk samples with known Lewis specificity 
were obtained from the mothers who were at the first stage of their breast-feeding. The 
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volume for isolation was 50 ml or 100 ml. The samples were stored at -20°C before 
isolation. Milk samples were melted in 37°C water bath and centrifuged at 4676 g for 
20 min at 4°C with centrifuge (Universal 32R, Hettich). The supernatant was filtrated by 
means of quartz wool and the aqueous phase was taken for the next step. The volume 
of the supernatant was determined. Then, double volume ethanol was added to the 
supernatant. Mixed sample was put on the ice overnight or at least 4 hours to remove 
the protein. After that, the sample was centrifuged and put on a rotate evaporation 
(Buechi, Essen, Germany) to remove the ethanol. With the above steps, most lipid and 
protein were removed. The following step of lactose removal was achieved by the 
Sephadex G25 gel filtration chromatography (HiPrep). The Sephadex G25 system was 
equipped with the column (HiPrep 26/10 Desalting) filled with Sephadex G-25-Fine, 
cross-linked dextran. The equipment was set up with 60 ml/h flow rate of pure water 
(Baxter) as solvent, with the injection volume of 5 ml. The detector was refractometer. 
The fractions were collected (Fraction collector, Frac-920, Amersham Biosciences, 
Sweden) from 1st to 60th tubes. Some fractions were analyzed by HPAEC-PAD to 
check the start of the fractions containing lactose. After this step, the complex HMO 
fractions contained neutral and acidic fractions were obtained.  
To separate the neutral and acidic HMO fractions from the whole HMO fractions, 
Normal Phase Anion Exchange Chromatography (Shimadzu) was utilized. The HPLC 
was equipped with a column called RESOURCE Q with the oven temperature 25°C, 6 
ml (Amersham Biosciences, Sweden) with the detector SPD-10A (wavelength: 214 nm, 
lamp: D2) and the pump LC-10AS. The solvent contained solvent A and B: solvent A 
was water and solvent B was 0.6 M NaCl. The flow of the solvent was 2.00 ml/min and 
the gradient was: from 0 to 7.5 min, 100% A; from 7.5 to 52 min, B was increased to 
100% with set points of 55% at time 50 min; in the next 3 min, B decreased to 50% and 
stayed the same for 5 min; in the last 5 min, the solvent returned to 100% A. The 
fractions were collected by Fraction collector FRC-10A (Shimadzu), from 1st to 130th 
fractions (1 ml). For the neutral HMO fractions, fractions were collected from 2 to 12 
min and were lyophilized directly. For the acidic HMO fractions, fractions were 
collected from 15 min to 65 min (end of collection) and lyophilized. Then the dried 
acidic fractions were diluted with water and subjected to gel filtration by Sephadex G25 
chromatography to remove the salt. The fraction after desalting was also analyzed by 
HPAEC-PAD. The sample was lyophilized and the acidic HMO fractions were 
obtained. 
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3.2.2 Analysis of HMO fractions and HMO standards 
After the isolation, neutral and acidic HMO fractions were identified by 
MALDI-TOF-MS to get the main components of each HMO fraction. For further 
analysis to quantify the HMO fractions, HPAEC-PAD was used. To analyze the HMO 
fractions in the microorganism cultivation study, 2-AA was used for labeling and 
RP-HPLC was used for analysis. The general information of these analytical methods 
was as following: 
 
MALDI-TOF-MS: Matrix Assisted Laser Desorption Ionization — Time of Flight-Mass 
Spectrometry. Mass spectra were recorded using an Ultraflex I instrument (Bruker 
Daltonics, Bremen, Germany), equipped with a nitrogen laser emitting at 337 nm; a 
dextran hydrolysate was used to calibrate the equipment and the analytical method 
according to Blank et al. 2011. Hundred single-laser pulse spectra were summed up 
for each mass spectrum. For analysis, a volume of 0.5 µl of 6-aza-2-thiothymine (ATT, 
Sigma Aldrich, St. Louis, USA) matrix (35 mM in 25 mM aqueous ammonium 
bicarbonate) solution was deposited on a MALDI AnchorChipTM 600 target plate 
(Bruker Daltonics) and mixed with 0.5 µl of the HMO sample. The matrix-sample spots 
were dried under a stream of cold air. Oligosaccharides profiles were acquired in 
positive-ion reflectron mode over a mass range of m/z 360–3000 according to Dotz et 
al. 2014. Data acquisition and analysis were performed by flexControl and flexAnalysis 
3.0 software (Bruker DaltonicsGermany), as well as GlycoWorkbench software tools, 
which have been developed as part of the EUROCarbDB project. 
 
HPAEC-PAD: High-pH anion-exchange chromatography with pulsed amperometric 
detection. HPAEC was performed on a Dionex ICS 5000 system (Thermo Fisher 
Scientific GmbH, Dreieich, Germany), equipped with a Dionex Carbopac PA-1 column 
(4 mm × 250 mm, temperature controlled at 30°C) in combination with a Carbopac 
PA-1 guard column (2 mm × 50 mm). Samples (15-30 µl) were injected by means of a 
Dionex AS-AP dual channel autosampler. The solvents contained solvent A and B: 
Solvent A was 100 mM sodium hydroxide (NaOH); Solvent B was 250 mM sodium 
acetate in 100 mM NaOH. The solvent flow was 0.5 ml/min and the gradient was: from 
0 to 15 min, 100% A; from 15 to 83 min, B was increased to 100% with set points of 
20% B at time 40 min and 60% B at 70 min; after 4 min of 100% B, the solvent was 
returned to 100% A within 2 min, followed by an 16 min equilibration. 
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RP-HPLC: Reversed-phase chromatography includes any chromatographic method 
that uses a hydrophobic stationary phase. RP-HPLC refers to liquid chromatography 
(Molnár and Horváth, 1976). RP-HPLC was performed on a Dionex ICS 5000 system 
(Thermo Fisher Scientific GmbH, Dreieich, Germany), equipped with a 
Thermo Scientific Syncronis C18 column (250 ×4.6, 10 mm guard, temperature 
controlled at 30°C) Samples (10-25 µl) were injected by means of a Dionex AS-AP 
dual channel autosampler. Buffer A was 150mM Na-Citrate, with 5% acetonitrile (ACN), 
pH 4.5; buffer B was 50 mM NH4-acetate, with 7.5% ACN, pH 4.0; LCMS-grade ACN 
was used as solvent C. The 0.5 ml/min solvent flow was isocratic (50% A, 50% B) for 
75 minutes, then the solvent was gradually changed during 25 min to (40% A, 40% B, 
20% C) and kept constant for 5 min. During the next 30 min initial conditions were 
gradually restored, followed by a 5 min equilibration (Leo et al., 2009). 
 
HPLC-Analysis for fatty acid detection: An ion exclusion chromatography was 
performed on a HPLC System S1000 Solvent Delivery System (Sykam, Eresing, 
Germany) with an oven (70°C). The column was CarboSep H Plus (7.8 mm x 300 mm, 
Transgenomic, Omaha, USA). Samples were filtrated by Whatman Spartan 30/20.2 
RC cellulose filters (Whatmann, Dassel, Germany) and the volume of 50 µl sample 
was injected by antosampler (S5200, Sykam, Eresing, Germany). The detector for the 
system was RI 2000-Detector (Schambeck SFD GmbH, Bad Honnef, Germany) 
operating at 40°C. The solvent was 5 mM H2SO4, and the flow rate was 0.3 ml/min. In 
standards mixture (1 mM), the following substances were added: Citrate, Malate, 
Succinate, Lactate, Formate, Acetate, Propionate, Butyrate, Valerate and Carbonate. 
3.2.3 Methods for preparation of mediums/buffers 
3.2.3.1 MRS medium (DSMZ medium 11) 
All the ingredients were dissolved one after the other in distilled water. The pH was 
adjusted to 6.0 to 6.5. Then the mixture was divided into 200 ml bottles. Then the 
media in the bottle was autoclaved at 121°C for 30 min. 
For pre-cultivation of bacteria, all the ingredients were dissolved. For the growth 
study of different saccharides, all the ingredients were dissolved except glucose. 
Sterilized glucose, galactose, lactose or HMO fractions were added right before 
inoculation. 
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3.2.3.2 Bifidobacterium medium 
    All the ingredients were dissolved one after the other except L-cysteine-HCl in 
distilled water. Then the mixture was autoclaved at 121°C for 40min. Then the medium 
was cooled to 98°C within the autoclave and was then cooled down under oxygen free 
gas (mixture of CO2 and N2) to avoid redissolving of oxygen. Sterilized L-cysteine-HCl 
was added into the medium and the pH was adjusted to 6.8, using 8 N NaOH. Then the 
medium was dispensed into 50 ml bottles under the same gas phase. 
3.2.3.3 Modified Reinforced Clostridial Broth 
All the ingredients were dissolved one after the other except L-cysteine-HCl in 
distilled water. The pH was adjusted to 6.8. Then the medium was autoclaved at 121°C 
for 40 min. Afterwards, the medium was brought at 98°C and further cooled down 
under oxygen free gas (mixture of CO2 and N2). Finally sterilized L-cysteine-HCl was 
added into the medium and the medium was dispensed the mixture into 50 ml bottles 
under the same gas phase. 
3.2.3.4 Buffer for RP-HPLC 
Buffer A (1L): 150 mM Na-Citrate, with 5% ACN, pH 4.5. 
Buffer B (1L): 50 mM NH4-Acetate, with 7.5% ACN, pH 4.0. 
Steps: 1. Weigh exact amount of solid chemicals: Na-Citrate: 44.11 g, NH4-acetate: 
3.85 g. 
      2. Melt the chemicals with about 200 ml water. 
      3. Filtrate the solvent with the 0.45 µm, 47 mm filter paper. 
      4. Add the exact volume of ACN: for buffer A: 50 ml, for buffer B: 75 ml. 
      5. Add some water to the solvent to about 900 ml.  
      6. Adjust the pH using 37% HCl to the expected pH. 
3.2.4 Cultivation of intestinal microorganism 
3.2.4.1 Activation 
The steps for activation of the bacteria from the ‘Freeze Dried’ bacteria in the glass 
tube are as follows: 
Steps: 1. Prepare the medium for the bacteria. 
          2. Open glass tube after outside disinfection with ethanol under sterilized 
condition, and take out the tube with dry bacteria inside. 
          3. Add 1 ml medium to the bacteria tube, mix with pipette, flush the tube 
with nitrogen if the bacteria is strict anaerobic.  
          4. Inoculate the 1 ml bacteria to the bottle with medium and cultivate in the 
culture room with proper temperature (37°C). 
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3.2.4.2 Pre-cultivation 
Each microoganism was cultivated starting with 50 ml or 100 ml medium. After 
reaching the highest density, new inoculation was made using a reduced medium 
volume with steps of 50 ml, 20 ml, 5 ml, and finally 2 ml or 1 ml for growth study with 
HMOs. In each new step, 10% from the original bacteria culture were inoculated. 
3.2.4.3 Cultivate with glucose, galactose and lactose 
L. lactis and L. acidophilus were grown on MRS medium (without glucose) to 
which different carbon substrates have been added. No carbon substrate was added to 
analysis growth on MRS medium (without glucose) as a growth control. Glucose was 
added in different concentration of 1 mM, 2 mM, 5 mM, and 10 mM, galactose was 
studied on different concentration of 1 mM, 2 mM, 5 mM, and 10 mM and lactose was 
added in different concentration of 1 mM, 2 mM, 5 mM, and 10 mM. The cultivation 
volume was 5 ml. Each concentration was performed in triplicate.  
3.2.4.4 Cultivate with HMO fractions and HMO standard 
All the seven microorganisms were cultivated with no carbon substrate (growth 
control), 1 mM HMO fractions (neutral or acidic) or 1 mM single HMO standard. HMO 
fractions included: LeA1, LeA2, LeA3, LeB1, LeB2, and Le0. Each HMO fraction 
contained neutral and acidic fractions. Single HMO standard included: 2’-FL, 3-FL, 
LNT, LNnT, 6’-SL. Each carbon substrate was performed in triplicate. 
3.2.4.5 Growth curves and growth rate calculation 
Growth curves were measured by OD500nm value using spectrophotometer. All 
samples (70 µl) from culture were measured in triplicate plus a blank every 1 or 2 h in 
the study with glucose, galactose and lactose. In HMO studies, all samples from 
culture were measured in triplicate plus a blank every 8 to 10 h. 
3.2.4.6 Microscope 
For routine investigation under the microscope (Zeiss microscope, Axiophot 2), 
normal carrier glass was used with the magnification 1000 fold.  
3.2.4.7 Storage 
For short storage, the liquid culture was stored at 4°C or the culture was frozen at 
-20°C. For long storage, agar dilution series were stored at 4°C after colonies have 
been grown.  
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3.2.4.8 Isolation or purification 
To isolate the bacteria from contamination, or purify bacteria, the agar dilution 
series had been performed. The steps are as follows: 
      1. Wash the agar three times and prepare the agar tubes (3 ml of 3% agar in a 
25 ml glass tube) before the bacteria isolation. 
      2. Warm the medium in the 60°C water bath; boil 7 to 8 agar tubes until melted. 
      3. Change stopper of the agar tubes and added 6 ml medium to each agar tube, 
and then put the tubes in the 45°C water bath. 
      4. Put one drop of liquid culture of the bacterium to the first agar tube, mix and 
then pour out about 1-2 ml from the first agar tube to the second tube, and so on, until 
the last tube. 
      5. Put the tube directly in the ice to cool down, and flush the tubes with 
anaerobic gas (nitrogen/carbon dioxide). 
      6. Incubate the tubes with bacteria in the culture room with 37°C, wait one or 
two weeks to get the single colony in the last two or three tubes. 
      7. Pick a single colony and inoculate either the next agar dilution series or liquid 
medium to get a pure bacteria. 
3.2.5 2-AA labeling and analysis by RP-HPLC 
3.2.5.1 Glycan labeling and 2-AA labeling 
Glycans may be derivatized to introduce a chromophore or fluorophore, facilitating 
detection after chromatographic or electrophoretic separation. 
Derivatization can also be applied to link charged or hydrophobic groups at the 
reducing end to enhance glycan separation and mass-spectrometric detection. 
2-AA labeling: 2-Aminobenzoic acid labeling via reductive amination (Figure3-2). 

Figure 3-2 Labeling of 2-Aminobenyoic acid (2-AA) via reductive amination (Ruhaak et al., 
2010). 
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During cultivation of bacteria with HMO fractions, samples (50 µl) for the RP-HPLC 
were taken at 0 h and at the end (24 h, 40 h or 48 h). Filtrated the samples with 
sterilized filter and the samples were dealt with 2-AA labeling for the analysis. 
3.2.5.2 Protocol for 2-AA labeling 
This protocol was according to previous studies (Bigge et al., 1995; Ruhaak et al., 
2008) with modifications. 
A. Preparation of fresh labeling solutions, described as following: 
1. Add 150 µl glacial acetic acid to 500 µl DMSO and mix well. 
2. Add 100 µl of this mixture to 4.8 mg (0.35 M) 2-AA labeling dye 
(2-Aminobenzoic acid, Sigma A-1506) and mix until dissolved. 
 3. Add total dye solution to 6.3 mg (1 M) reluctant NaCNBH3 (Sodium 
cyanoborohydride, Fluka 71435) and mix well. 
 4. Add 5ul of labeling reagent to each dried samples, put lid on and mix. 
5. Incubate 2-3 h at 65°C, vortex every 30 min, centrifuge after each vortexing 
step. 
 6. After incubation, centrifuge shortly and let it cool down to room temperature. 
 7. Add 100 µl water to transfer to C18 column (C18 Sep-Pak light, Water WAT 
023501.130 mg). 
B. Removal of excess of labeling reagents by Sep-Pak C18 column, the steps 
are as following: 
 1. Before use of Sep-Pak C18, wash with 1 ml MeOH and 2 ml H2O. 
 2. Add sample in max volume 500 µl on C18 column. 
 3. Wash the column with 2 ml H2O. 
 4. Elute with 1 ml 50% MeOH and collect in bottle. 
 5. Dry with N2 or by Speed-vac. 
3.2.5.3 Analyze the substrates from cultivation by RP-HPLC. 
After 2-AA labeling of samples from cultivation experiment, the samples were 
dried. 100 µl water was added to each bottle and 70 µl was taken for analysis by 
RP-HPLC. The method for RP-HPLC was described in 3.2.2. 
3.2.6 Analysis of metabolic products 
During cultivation of bacteria with HMO fractions, samples (70 µl) for analyze the 
metabolic products were taken at 0 h, 15 h and at the end (24 h, 40 h or 48 h). The 
samples were stored in -20°C. Before analysis by HPLC, the samples were taken out 
of the freezer, thawed and immediately centrifuged (11430 g, 5 min). The supernatant 
was put into vials for HPLC. The inject volume for the HPLC was 50 µl. Peaks were 
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identified based on the retention time and in comparison with the standards. Table 3-5 
shows the measured areas of different concentrations of various standards. Figure 3-3 
and 3-4 show the calibration of standards. 
Table 3-5 Measured peak areas (means) of different concentrations of various standards 
 
 
Figure 3-3 Calibration of mixture of six standard. The standards were as follows: glucose, 
lactate, formate, acetate, propionate and ethanol. 
 
Figure 3-4 Calibration of standard lactate. The linear equation (y) and coefficient of 
delimitation (R2) were shown.
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Calibration of Mixture of 6 standard (50µl) 
µM 200 400 600 800 1000 
Glucose 36,18 73,095 109,71 148,27 190,05 
Lactate 8,01 16,48 29,56 38,665 49,38 
Formate 6,19 9,81 14,875 20,525 27,08 
Acetate 4,01 9,355 13,3 19,515 28,15 
Propionate 0 1,925 6,65 8,805 11,115 
Ethanol 0 0 0 1,32 1,75 
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4 Results 
4.1 Isolation and separation of HMO fractions from human milk 
4.1.1 Results from Sephadex G25 gel filtration 
Human milk samples were delipidated by centrifugation and treated by ethanol to 
remove proteins. Then, the supernatant was subjected to Sephadex G25 gel filtration 
chromatography to remove the most part of lactose in the human milk samples. From the 
chromatogram of the milk carbohydrate fractions, the elution of lactose can be identified. 
Fractions with lactose were discarded. The fraction with lactose start point was taken for 
analysis using HPAEC-PAD to check the amount of lactose in the fraction. Figure 4-1 
shows the HPAEC-PAD chromatogram of the specific fraction from Sephadex G25 gel 
filtration. As can be seen in Figure 4-1, this fraction contains little lactose (retention time 
would be 20.7 min). 
 
Figure 4-1 HPAEC-PAD chromatogram of a Sephadex G25 fraction eluting from the 
column immediately before the lactose peak. The flow rate was 1.00 ml/min; the eluent was 
100 mM NaOH plus 250 mM NaAc. 
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4.1.2 Separation of complex HMO fractions into neutral and acidic 
fractions using Normal Phase Anion Exchange Chromatography  
After Sephadex G25 gel filtration chromatography, most part of lactose was 
discarded and the complex HMO fractions were obtained. To separate neutral and acidic 
HMO fractions, the lactose-free carbohydrate fraction was subjected to Normal Phase 
Anion Exchange Chromatography according to Kunz et al. 1996. During the separation, 
the neutral HMO fractions were eluted within 12 min and the acidic HMO fractions from 
12 to 60 min using 250 mM NaAc in buffer B.  
4.1.3 Desalting of acidic HMO fractions 
After Normal Phase Anion Exchange Chromatography, the neutral and acidic HMO 
fractions (the latter containing large amounts of salt) were collected. For the neutral HMO 
fractions, lyophilization was used to dry the samples. The acidic fractions with salt were 
subjected to Sephadex G25 gel filtration chromatography again to remove the salt. From 
the chromatography, the peak of salt was acquired and the fraction immediately before 
salt peak was taken for analysis using HPAEC-PAD to check the amount of salt in the 
fraction. Figure 4-2 shows the HPAEC-PAD chromatogram of the specific fraction from 
Sephadex G25 gel filtration for desalting. 
 
Figure 4-2 HPAEC-PAD chromatogram of a Sephadex G25 fraction eluting from the 
column immediately before the salt peak. The flow rate was 1.00 ml/min; the eluent was 100 
mM NaOH plus 250 mM NaAc. 
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4.1.4 Neutral and acidic HMO fractions 
After desalting by Sephadex G25 gel filtration, the acidic HMO fractions were 
obtained. Lyophilization was used to dry the samples and the samples were weighed 
separately. The amounts of each fraction are shown in Table 4-1. The neutral and acidic 
HMO fractions were analyzed using HPAEC-PAD, the chromatograms are shown in 
Figure 4-3. Then, the samples were dissolved with pure water with final concentration of 
10 mg/ml for analysis and for growth studies with microorganisms. 
Table 4-1 Amount of neutral and acidic HMO fractions isolated from human milk samples 
Human milk 
sample 
Lewis 
Specificity 
Volume of 
milk sample 
(ml) 
Amount of 
neutral HMO 
fractions (mg) 
Amount of 
acidic HMO 
fractions (mg) 
LeA1 Lewis a 50 80 70 
LeA2 Lewis a 100  274 290 
LeA3 Lewis a 100  170 110 
LeB1 Lewis b 100  230 210 
LeB2 Lewis b 50  110 100 
Le0 Lewis 0 100  230 160 
 
As shown in the Table 4-1, there are in total seven human milk samples in which 
three samples are from the mothers with Lewis A blood specificity, two samples are from 
mothers with Lewis B blood specificity and one sample was from the mother with Lewis 
negative blood specificity. The volume of the human milk samples and the amount of 
neutral and acidic HMO fractions isolated from the human milk samples are listed. The 
starting volume of the milk samples was 50 ml or 100 ml. The amount of neutral HMO 
fractions arranged from 80 mg to 274 mg, and the amount of acidic HMO fractions were 
from 70 mg to 290 mg. 
 
 
 
 
Results 
 
39 
 
(a) neutral HMO fraction 
 
(b) acidic HMO fraction 
 
Figure 4-3 HPAEC-PAD chromatogram of (a) a neutral HMO fraction and (b) an acidic HMO 
fraction. 
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4.2 MALDI-TOF-MS of HMO fractions 
All the neutral HMO fractions as well as neutral single HMO standards were 
analyzed by MALDI-TOF-MS. For further analysis, the samples were chemically modified 
with 2-Aminobenzoic acid (2-AA) after the growth study with various microorganisms. To 
check this labeling method as well as to compare the samples before and after labeling, 
the MALDI-TOF-MS was also utilized. The profiles of oligosaccharides were acquired in 
positive – ion reflectron mode over a mass range of m/z 360-3000. Table 4-2 lists the 
range of m/z and the correspondent chemical composition. Figure 4-4 shows the 
MALDI-TOF-MS spectra of HMO fractions before or after 2-AA labeling. 
 
Table 4-2 The range of m/z and the correspondent chemical composition of the detected 
HMO 
m/z  
[M+Na]+ 
Chemical  
composition 
m/z  
[M+Na]+ 
Chemical  
composition 
511 2´-FL 
Hex2Fuc1 
1387 dFLNH 
Hex4HexNAc2Fuc2 
657 dFL 
Hex2Fuc2 
1533 tFLNH 
Hex4HexNAc2Fuc3 
730 LNT/LNnT 
Hex3HexNAc1 
1606 Hex5HexNAc3Fuc1 
876 LNFP 
Hex3HexNAc1Fuc1 
1752 Hex5HexNAc3Fuc2 
1022 dFLNT 
Hex3HexNAc1Fuc2 
1825 Hex6HexNAc4 
1095 LNH 
Hex4HexNAc2 
1898 Hex5HexNAc3Fuc3 
1241 FLNH 
Hex4HexNAc2Fuc1 
  
 
From Table 4-2, the m/z values of the detected components are described. The 
main components have the m/z range from 511 to 1898. From the m/z, the chemical 
composition can be acquired. The Hex-term means Hexose-unit, Fuc represent 
Fucose-unit, HexNAc means N-Acetylglucosamin-unit. 2’-FL is also Hex2Fuc1 because 
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it constitutes of two Hexose-units and one Fucose-unit. LNT and LNnT are also 
Hex3HexNAc because they built with three Hexose-units and one N-Acetylglucosamin 
-unit. LNFP is also Hex3HexNAc1Fuc1 because it constitutes of three Hexose-units, one 
N-Acetylglucosamin-unit and one Fucose-unit. 
    Due to 2-AA labeling the m/z-values differ from unlabeled samples, the spectra after 
2-AA labeling showed the m/z value that is 97 higher than the original m/z value in the 
table. For example, the m/z of LNT/LNnT is 730 before labeling, and after 2-AA labeling, 
the value increase to 827. 
 
(a) Neutral HMO fractions from a LeA1 milk sample before 2-AA labeling 
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(b) Neutral HMO fractions from LeA1 milk sample after 2-AA labeling 
 
(c) Neutral HMO fractions from LeB2 milk sample before 2-AA labeling 
 
 
 
 
 
Results 
 
43 
 
(d) Neutral HMO fractions from LeB2 milk sample after 2-AA labeling 
 
   (e) Neutral HMO fractions from Le0 before labeling 
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        (f) LNT after 2-AA labeling 
 
(g) 2’-FL, 3-FL, LNFPI after 2-AA labeling
 
Figure 4-4 MALDI-TOF-MS spectra of HMO fractions before or after 2-AA labeling. (a) 
Neutral HMO fractions from a milk sample LeA1 before 2-AA labeling. (b) Neutral HMO fractions 
from milk sample LeA1. (c) Neutral HMO fractions from LeB2 milk sample. (d) Neutral HMO 
fractions from LeB2 milk sample. (e) Neutral HMO fractions from Le0. (f) Single HMO standards of 
LNT (g) and 2’-FL, 3-FL, LNFPI. 
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4.3 Analysis of HMO fractions by HPAEC-PAD 
After the analysis by MALDI-TOF-MS, all the neutral and acidic HMO fractions were 
analyzed by HPAEC-PAD. Table 4-3 shows the retention time of single HMO standard. 
Figure 4-5 shows the chromatograms from three neutral HMO fractions and one acidic 
HMO fraction. 
Table 4-3 Retention time of single HMO standard for HPAEC-PAD 
HMO Retention       
time (min) 
HMO Retention      
time (min) 
LNDFH II 10 LNFP I 31,1 
LNDFH I     13,9 LNT  41,2 
3-FL  14,2 Sial-acid  45,3 
LNFP III  16 LST c  57,0 
LNFP II  16,6 6'-SL  58,0 
LDFT  18,5 3'-SL  59,2 
Lactose  20,7 LST a  63 
LNnT  34,9 LST b  65 
LNFP V  25 DS-LNT  81 
2'-FL  26,4   
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(b) 
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   (d) 
 
Figure 4-5 Chromatograms of the HMO fractions from samples by HPAEC-PAD. (a) neutral 
HMO fraction from milk sample LeA1. (b) acidic HMO fraction from milk sample LeA1. (c) neutral 
HMO fractions from milk sample LeB2. (d) neutral HMO fractions from milk sample Le0. 
 
4.4 Growth study of microorganisms on glucose, galactose and 
lactose  
To investigate the effect of different concentrations of glucose, galactose and 
lactose on the microorganisms, Lactococcus lactis subsp. lactis and Lactobacillus 
acidophilus were studied. The medium for Lactococcus lactis subsp. lactis was MRS 
medium (without glucose), and different concentrations of glucose, galactose or lactose 
were added later. The medium for Lactobacillus acidophilus was MRS medium (without 
glucose) with L-cysteine, and different concentrations of glucose, galactose or lactose 
were added later.  
Figure 4-6 shows the growth curves of L. acidophilus at various concentrations (0 
mM, 1 mM, and 2 mM) of glucose, galactose or lactose. Figure 4-7 shows the growth 
curves of L. lactis at various concentrations (0 mM, 1 mM, 2 mM and 5 mM) of glucose, 
galactose or lactose. 
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Figure 4-6 Growth curves of L. acidophilus grown in MRS medium (without glucose) on 
various concentrations of glucose, galactose or lactose 
 
The growth curves showed that the OD500nm of L. acidophilus could reach about 0.2 
without any carbon substrate added. When 1 mM glucose or galactose added, the 
OD500nm increased to 0.3. When the concentration increased to 2 mM, the OD500nm 
continued to increase to 0.4. When 1 mM lactose added, the OD500nm was similar to 2 mM 
glucose or galactose added. When the concentration of lactose increased to 2 mM, the 
OD500nm could reach as high as 0.6. The growth curves showed that L. acidophilus could 
grow on glucose, galactose and lactose. 
 
  
Figure 4-7 Growth curves of L. lactis grown in MRS medium (without glucose) on various 
concentrations of glucose, galactose (left) or lactose (right). 
 
The growth curves showed that the OD500nm of L. lactis could reach about 0.4 without 
any carbon substrate added. When 1 mM glucose or galactose added, the OD500nm 
increased to 0.5 to 0.6. When the concentration increased to 2 mM, the OD500nm of 
glucose continued to increase to about 0.7, while the OD500nm of galactose decreased 
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back to 0.4. When the concentration of galactose increased to 5 mM, the OD500nm stayed 
the same as 2 mM. When 1 mM lactose added, the OD500nm could reach about 0.65. 
When the concentration increased to 2 mM, the OD500nm decreased back to about 0.45. 
When increased to 5 mM, the OD500nm increased to 0.5, but still lower than with 1 mM 
glucose, galactose or lactose. The results showed that L. lactis could grow on glucose, 
low concentration of galactose or lactose. 
 
4.5 Growth study of microorganisms on HMO fractions and HMO 
standard 
4.5.1 Lactococcus lactis subsp. lactis 
To investigate the effect of HMOs on the growth of Lactococcus lactis subsp. lactis, 
1 mM HMOs (neutral and acidic HMOs, as well as five single HMO standards) were used 
as sole carbon substrate in MRS medium, replacing glucose. Other carbon substrates, 
including glucose, galactose and lactose with the same concentration were also 
analyzed for comparison. Medium without carbon substrate was used as control. Figure 
4-8 shows the growth curves of L. lactis on different carbon substrates. 
 
(a) Glc, Gal, Lac                              LeA2 
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(b) LeA1                                     LeA3 
  
 
(c) LeB1                                     LeB2 
  
 
(d) Le0                                       6’-SL 
  
 
 
 
Results 
 
51 
 
(e) 2’-FL, 3’-FL                                LNT, LNnT 
  
Figure 4-8 Growth curves of L. lactis grown in MRS medium (without glucose) on different 
carbon substrate. (a) Glucose, galactose, and lactose (left), as well as neutral and acidic HMO 
fractions from LeA2 (right). (b) Neutral and acidic HMO fractions from LeA1 (left) and LeA3 (right). 
(c) Neutral and acidic HMO fractions from LeB1 (left) and LeB2 (right). (d) Neutral and acidic HMO 
fractions from Le0 (left) and single HMO standard 6’-SL (right). (e) Single HMO standard 2’-FL, 
3-FL (left) and LNT, LNnT (right). 
 
 
The growth curves show that L. lactis could reach maximum OD500nm in about 25 
hours. The maximum OD500nm without carbon substrate was about 0.4. When 1 mM 
glucose or galactose was added, the growth increased and the maximum OD500nm could 
reach about 0.5 to 0.6. With 1 mM lactose, the maximum OD500nm was higher than 0.6. 
When 1 mM neutral or acidic HMOs added, the growth with neutral HMOs was better 
than the growth with lactose, the maximum OD500nm with acidic HMOs were lower than 
with neutral HMOs except the case with LeA2. The growth with five single HMO 
standards showed that the maximum OD500nm with 6’-SL and 3-FL were higher than that 
with lactose, LNT showed a similar OD500nm with lactose, while the maximum OD500nm 
with 2’-FL and LNnT were lower. 
 
4.5.2 Lactobacillus acidophilus 
To investigate the effect of HMOs on the growth of Lactobacillus acidophilus, similar 
experiments were done according to L. lactis with the modification of adding L-cysteine in 
the MRS medium. Figure 4-9 shows the growth curves of L. acidophilus on different 
carbon substrates. 
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(a) Glc, Gal, Lac                              LeA1 
  
 
(b) LeA2                                     LeA3 
  
   
(c) LeB1                                     LeB2 
  
 
 
 
 
Results 
 
53 
 
(d) Le0                                      2’-FL, 3-FL 
  
 
(e) LNT, LNnT                                6’-SL 
  
Figure 4-9 Growth curves of L. acidophilus grown in MRS medium with L-Cysteine 
(without glucose) on different carbon substrates. (a) Glucose, galactose, and lactose (left), as 
well as neutral and acidic HMO fractions from LeA1 (right). (b) Neutral and acidic HMO fractions 
from LeA2 (left) and LeA3 (right). (c) Neutral and acidic HMO fractions from LeB1 (left) and LeB2 
(right). (d) Neutral and acidic HMO fractions from Le0 (left) and single HMO standard 2’-FL, 3-FL 
(right). (e) Single HMO standard LNT, LNnT (left) and 6’-SL (right). 
 
 
 
The growth curves showed that L. acidophilus could reach maximum OD500nm in 
about 17 hours. The maximum OD500nm without carbon substrate was about 0.35. When 
1 mM glucose and galactose added, the growth was increased; the maximum OD500nm 
could reach about 0.45 with galactose and about 0.1 higher than that with glucose. With 
1 mM lactose, the maximum OD500nm was about 0.6. When 1 mM neutral or acidic HMOs 
added, the growths with neutral HMOs were all better than the growth with lactose, the 
maximum OD500nm with acidic HMOs were lower than with neutral HMOs. The growth 
with five single HMO standards showed that the maximum OD500nm with 2’-FL, LNT and 
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6’-SL were higher than lactose, while the maximum OD500nm with 3-FL and LNnT were 
lower than lactose, but higher than glucose. 
 
4.5.3 Bifidobacterium longum subsp. infantis 
To investigate the effect of HMOs on the growth of Bifidobacterium longum subsp. 
infantis, similar experiments were done according to L. lactis with the modification of 
changing the MRS medium to Bifidobacterium medium. Figure 4-10 shows the growth 
curves of B. infantis on different carbon substrates. 
 
(a) Glc, Gal, Lac                              LeA1 
  
(b) LeA2                                     LeA3 
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(c) LeB1                                    LeB2 
  
(d) Le0                                      2’-FL, 3-FL 
  
(e) LNT, LNnT                               6’-SL 
  
Figure 4-10 Growth curves of B. infantis grown in Bifidobacterium medium (without 
glucose) on different carbon substrates. (a) Glucose, galactose, and lactose (left), as well as 
neutral and acidic HMO fractions from LeA1 (right). (b) Neutral and acidic HMO fractions from 
LeA2 (left) and LeA3 (right). (c) Neutral and acidic HMO fractions from LeB1 (left) and LeB2 (right). 
(d) Neutral and acidic HMO fractions from Le0 (left) and single HMO standard 2’-FL, 3-FL (right). 
(e) Single HMO standard LNT, LNnT (left) and 6’-SL (right). 
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The growth curves showed that B. infantis could reach maximum OD500nm in about 
24 hours. The maximum OD500nm without carbon substrate was about 0.6. When 1 mM 
glucose or galactose was added, the growth rate was increased; the maximum OD500nm 
reached between 0.7 and 0.8. With 1 mM lactose, the maximum OD500nm was higher, 
reached about 0.9. When 1 mM neutral or acidic HMOs added, the growth with six 
neutral HMOs were all better than the growth with glucose, in which three of neutral 
HMOs reach higher OD500nm than with lactose, one of neutral HMOs reach the similar 
OD500nm as with lactose. The maximum OD500nm with acidic HMOs was lower than with 
neutral HMOs. The growth with five single HMO standards showed that the maximum 
OD500nm with LNT was higher than lactose, while the maximum OD500nm with 2’-FL, 3-FL 
and LNnT were between glucose and lactose. The maximum OD500nm with 6’-SL was 
similar to with glucose. 
 
 
4.5.4 Bifidobacterium longum subsp. infantis vs. Bifidobacterium 
longum subsp. longum 
To compare the effect of HMOs on the growth of Bifidobacterium longum subsp. 
infantis and Bifidobacterium longum subsp. longum, the same experiments were done 
according to B. infantis together with B. longum. Figure 4-11 shows the growth curves of 
B. infantis vs. B. longum on different carbohydrate substrates. 
 
(a) Glc, Gal, Lac                              LeA1 
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(b) LeA2                                    LeA3 
  
 
(c) LeB1                                    LeB2 
  
 
(d) Le0                                      2’-FL, 3-FL 
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(e) LNT, LNnT                               6’-SL 
  
Figure 4-11 Growth curves of B. infantis and B. longum grown in Bifidobacterium medium 
(without glucose) on different carbon substrates. (a) Glucose, galactose, and lactose (left), as 
well as neutral and acidic HMO fractions from LeA1 (right). (b) Neutral and acidic HMO fractions 
from LeA2 (left) and LeA3 (right). (c) Neutral and acidic HMO fractions from LeB1 (left) and LeB2 
(right). (d) Neutral and acidic HMO fractions from Le0 (left) and single HMO standard 2’-FL, 3-FL 
(right). (e) Single HMO standard LNT, LNnT (left) and 6’-SL (right). 
 
 
The growth curves showed that B. infantis and B. longum could both reach the 
maximum OD500nm in about 25 hours. The growth of B. infantis was better than that of B. 
longum on all the carbon substrates. The maximum OD500nm without carbon substrate of 
the two bacteria were similar, between 0.4 and 0.5. When 1 mM glucose or galactose 
was added, the growth rates both bacteria were increased; the maximum OD500nm of B. 
infantis could reach around 0.7; while the maximum OD500nm of B. longum could reach 
about 0.6. With 1 mM lactose, the maximum OD500nm of B. infantis was higher, reached 
about 0.85, while the maximum OD500nm of B. longum was about 0.8. When 1 mM neutral 
or acidic HMOs was added, both bacteria showed that the growths with neutral HMOs 
were better than with acidic HMOs. The maximum OD500nm with acidic HMOs for both 
bacteria were lower than with neutral HMOs, but higher than without carbon substrate. 
The growths with five single HMO standards showed that the maximum OD500nm with four 
neutral standards were higher than that with the acidic standard 6’-SL. The results with 
2’-FL and 3-FL showed that the maximum OD500nm with B. infantis were more than 0.1 
higher for both substrates than with B. longum. The OD500nm with 3-FL with both bacteria 
was about 0.1 higher than with 2’-FL. The study with LNT and LNnT showed that for B. 
infantis, the maximum OD500nm with LNT was about 0.1 higher than with LNnT, while for B. 
longum, LNT showed a similar OD500nm as LNnT. 
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4.5.5 Bacteroides vulgatus 
To investigate the effect of HMOs on the growth of Bacteroides vulgatus, similar 
experiments were done according to L. lactis with the modification of changing the MRS 
medium to Modified Reinforced Clostridial Broth. Figure 4-12 shows the growth curves of 
B. vulgatus on different carbon substrates. 
 
(a) Glc, Gal, Lac                              LeA1 
  
 
(b) LeA2                                     LeA3 
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(c) LeB1                                     LeB2 
   
 
(d) Le0                                      2’-FL, 3-FL 
  
 
(e) LNT, LNnT                               6’-SL 
  
Figure 4-12 Growth curves of B. vulgatus grown in Modified Reinforced Clostridial Broth 
(without glucose) on different carbon substrates. (a) Glucose, galactose, and lactose (left), as 
well as neutral and acidic HMO fractions from LeA1 (right). (b) Neutral and acidic HMO fractions 
from LeA2 (left) and LeA3 (right). (c) Neutral and acidic HMO fractions from LeB1 (left) and LeB2 
(right). (d) Neutral and acidic HMO fractions from Le0 (left) and single HMO standard 2’-FL, 3-FL 
(right). (e) Single HMO standard LNT, LNnT (left) and 6’-SL (right). 
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The growth curves showed that B. vulgatus could reach maximum OD500nm in about 
24 hours. The maximum OD500nm without substrate was about 0.45. When 1 mM glucose 
and galactose added, the growth was increased; the maximum OD500nm could reach 0.6 
to 0.7. With 1 mM lactose, the maximum OD500nm was higher, reached about 0.75. When 
1 mM neutral or acidic HMOs added, the growth with neutral HMOs was better than the 
growth with lactose in most cases. The maximum OD500nm with acidic HMOs were lower 
than with neutral HMOs except the case with LeA3.The growth with five single HMO 
standards showed that the maximum OD500nm with 2’-FL, LNT and LNnT were higher 
than lactose, while the maximum OD500nm with 3-FL was similar to with lactose. The 
maximum OD500nm with 6’-SL was similar to that with glucose. 
 
 
 4.5.6 Cronobacter sakazakii 
To investigate the effect of HMOs on the growth of Cronobacter sakazakii, similar 
experiments were done according to L. lactis with MRS medium. Figure 4-13 shows the 
growth curves of C. sakazakii on different carbon substrates. 
 
(a) Glc, Gal, Lac                             LeA1 
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(b) LeA2                                    LeA3 
  
 
(c) LeB1                                    LeB2 
  
 
(d) Le0                                      2’-FL, 3-FL 
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(e) LNT, LNnT                               6’-SL 
  
Figure 4-13 Growth curves of C. sakazakii grown in MRS medium (without glucose) on 
different carbon substrates. (a) Glucose, galactose, and lactose (left), as well as neutral and 
acidic HMO fractions from LeA1 (right). (b) Neutral and acidic HMO fractions from LeA2 (left) and 
LeA3 (right). (c) Neutral and acidic HMO fractions from LeB1 (left) and LeB2 (right). (d) Neutral 
and acidic HMO fractions from Le0 (left) and single HMO standard 2’-FL, 3-FL (right). (e) Single 
HMO standard LNT, LNnT (left) and 6’-SL (right). 
 
 
The growth curves showed that C. sakazakii could reach maximum OD500nm in about 
24 hours. The maximum OD500nm without carbon substrate was about 0.75. When 1 mM 
glucose and galactose added, the growth rate was increased; the maximum OD500nm 
could reach 0.8 to 0.9. With 1 mM lactose, the maximum OD500nm was higher, reached 
about 1.1. When 1 mM neutral HMOs added, the growth with six neutral HMOs were all 
better than the growth without glucose, in which one of neutral HMOs reached the 
OD500nm similar to with lactose, three of neutral HMOs reached the OD500nm between with 
lactose and with glucose, OD500nm of the rest two neutral HMOs were lower than with 
glucose. The maximum OD500nm with 1 mM acidic HMOs were all lower than with neutral 
HMOs, and the OD500nm were mostly lower than with glucose except the case with mother 
2 from Lewis a specificity. The growth with five single HMO standards showed that the 
maximum OD500nm with 3’-FL was higher than with glucose, the maximum OD500nm with 
2’-FL, LNT, LNnT and 6’-SL were all a little bit lower than with glucose. The maximum 
OD500nm with 6’-SL was similar to without glucose. 
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4.5.7 Akkermansia muciniphila 
To investigate the effect of HMOs on the growth of Akkermansia muciniphila, similar 
experiments were done according to L. lactis with the modification of changing the MRS 
medium to Modified Reinforced Clostridial Broth. Figure 4-14 shows the growth curves of 
A. muciniphila on different carbon substrates. 
 
(a) Glc, Gal, Lac                              LeA1 
  
 
(b) LeA2                                     LeA3 
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(c) LeB1                                     LeB2 
  
(d) Le0                                      2’-FL, 3-FL 
  
(e) LNT, LNnT                                6’-SL 
  
 
Figure 4-14 Growth curves of A. muciniphila grown in Modified Reinforced Clostridial 
Broth (without glucose) on different carbon substrates. (a) Glucose, galactose, and lactose 
(left), as well as neutral and acidic HMO fractions from LeA1 (right). (b) Neutral and acidic HMO 
fractions from LeA2 (left) and LeA3 (right). (c) Neutral and acidic HMO fractions from LeB1 (left) 
and LeB2 (right). (d) Neutral and acidic HMO fractions from Le0 (left) and single HMO standard 
2’-FL, 3-FL (right). (e) Single HMO standard LNT, LNnT (left) and 6’-SL (right). 
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The growth curves showed that A. muciniphila could reach maximum OD500nm in 
about 30 hours. The maximum OD500nm without carbon substrate was about 0.5. When 1 
mM glucose and galactose added, the growth rate was increased; the maximum OD500nm 
of glucose can reach about 0.8, while the maximum OD500nm of galactose was about 0.7. 
With 1 mM lactose, the maximum OD500nm was higher, reached about 0.85. When 1 mM 
neutral HMOs added, the growth with six neutral HMOs were all better than the growth 
without glucose, in which two of neutral HMOs reached the OD500nm higher than with 
lactose, two of neutral HMOs reached the OD500nm similar to with glucose, OD500nm of the 
rest two neutral HMOs were lower than with glucose. The maximum OD500nm with 1 mM 
acidic HMOs were all lower than with neutral HMOs, and the OD500nm were all lower than 
with glucose. The growth with five single HMO standards showed that the maximum 
OD500nm with 2’-FL, 3-FL and 6’-SL were lower than with glucose, among which 6’-SL is 
the highest. The maximum OD500nm with LNT, LNnT were similar to with glucose. The 
growth with LNT was better than with LNnT. 
4.6 Analysis of substrates in the medium before and after 
cultivations 
During the cultivation of each microorganism with different carbon substrates, 50 µl 
was taken from each sample at the beginning (0 h) and at the end (after 24 to 40 h 
depending on different bacteria). All the samples were labeled with 2-AA and analyzed 
via RP-HPLC. Table 4-4 shows the retention time of single HMO standards as well as the 
internal standard IS3 and 2-AA by RP-HPLC. Figure 4-15 shows the chromatogram of 
carbon substrate in the medium before and after cultivations by B. infantis and B. longum. 
Figure 4-16 shows the chromatogram of carbon substrate in the medium before and after 
cultivation by B. vulgatus. 
    Table 4-4 Retention time of single HMO standard by RP-HPLC after 2-AA labelling 
HMO Retention 
time (min) 
HMO Retention  
time (min) 
6‘-SL 31,0 IS3 64,0 
3-FL 46,4 LNT 67,0 
LNFP II 54,8 Lactose 72,5 
LNFP III    55,1 2’-FL 87,6 
LNnT 60,7 2-AA 94,4 
LDFT 61,0   
LNFP I  62,0   
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(a) lactose 
 
  
(b) LeA3n 
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(c) LeA3a 
 
  
(d) LeB2n 
 
  
 
 
Results 
 
69 
 
(e) LeB2a 
 
  
 
(f) Le0n 
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(g) Le0a 
 
  
(h) LNnT 
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(i) 2’-FL 
 
  
(j) 3-FL 
 
Figure 4-15 RP-HPLC Chromatograms of different carbon substrates in the medium before (black) and after cultivation by B. infantis 
(blue) and B. longum (green). The carbon substrates were as follows: (a) lactose; (b) neutral HMO fractions from LeA3; (c) acidic HMO fractions 
from LeA3; (d) neutral HMO fractions from LeB2; (e) acidic HMO fractions from LeB2; (f) neutral HMO fractions from Le0; (g) acidic HMO fractions 
from Le0; (h) single standard LNnT; (i) single standard 2’-FL; (j) single standard 3-FL. 
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The chromatograms from Figure 4-15 show the amount of different carbon 
substrates before and after cultivation of microorganisms. The results from lactose (a) 
showed that lactose could be nearly totally metabolized by B. infantis, while the amount 
of lactose after metabolizing by B. longum was higher. In the chromatogram of neutral 
HMO fractions from LeA3 (b), there were eight main peaks, which represented the 
components. After cultivation, both bacteria metabolized the components from four 
peaks. For the other four peaks, B. infantis could also metabolize them, while B. longum 
could only metabolize two of them to some extent and could not metabolized the other 
two. For B. longum, there were two new peaks, which may derive from semi-metabolized 
products during the cultivation. The results of the chromatogram of acidic HMO fractions 
from LeA3 (c) showed the similar results to neutral HMO fractions. From a total of more 
than 10 peaks, B. infantis could metabolize almost all the components, while B. longum 
could not metabolize the components from four peaks. From the results of neutral HMO 
fractions of LeB2 (d), B. infantis could also metabolize all the components, while B. 
longum could not metabolized three peaks of components. From the results of acidic 
HMO fractions of LeB2 (e), B. infantis could metabolize most of the components, except 
components from two small peaks. B. longum could not metabolize four peaks of 
components and produced two new peaks of components during cultivation. In Figure 
4-15 (f) and (g), the results from neutral and acidic HMO fractions of Lewis negative 
samples metabolized by both microorganisms were shown. B. infantis could metabolize 
both neutral and acidic HMO fractions. B. longum could metabolize most of the neutral 
HMO fractions, only two peaks were not totally degraded. And B. longum could 
metabolize the acidic HMO fractions to some extent for most of the peaks of components. 
The results from single standard LNnT (h) showed that B. infantis could metabolize LNnT, 
while B. longum could only metabolize the components to some extent and the new peak 
showed the products during cultivation. In Figure 4-15 (i) and (j), the results from single 
standards 2’-FL and 3-FL were shown. Both standards contained two peaks, in which 
one of the peaks (72min) stayed the same in both chromatograms. From the 
chromatograms, similar results could be obtained. B. infantis could metabolize both 2’-FL 
and 3-FL, while B. longum could only metabolize the two single standards to some 
extent. 
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     (a) Le0n 
 
 
 
 
(b) Le0a 
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(c) 6’-SL 
 
Figure 4-16 RP-HPLC Chromatograms of different carbon substrates in the medium before (black) and after cultivation by B. vulgatus 
(blue). The carbon substrates were as follows: (a) neutral HMO fractions from Le0; (b) acidic HMO fractions from Le0; (c) single standard 6’-SL. 
 
 
The chromatograms from Figure 4-16(a) showed that after cultivation, most of carbon substrates of neutral HMO fractions from 
Lewis negative could be metabolized by B. vulgatus, and during the cultivation, a new peak of components was produced. In Figure 
4-16(b), the chromatograms showed that most components of acidic HMO fractions from Lewis negative could be metabolized by B. 
vulgatus, and in the meanwhile, two peaks of components were increased and there was also one new peak appeared. For the single 
standard 6’-SL, the peak of 6’-SL was largely decreased, but there were some peaks increased after the cultivation.
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4.7 Analysis of metabolic products of cultivation 
To investigate the metabolic products of cultivation, the samples were taken for 
HPLC at the 0 h, 15 h and 40 h from cultivation. The amount of glucose, lactate, 
formate and acetate were quantified by HPLC analysis. Figure 4-17 shows the 
amount of glucose and metabolic products from the culture of B. infantis on different 
carbon substrates, such as glucose, galactose, lactose, neutral and acidic HMO 
fractions, as well as single HMO standards. Figure 4-18 shows the amount of glucose 
and metabolic products from the culture of B. longum on different carbon substrate, 
such as glucose, galactose, lactose, neutral and acidic HMO fractions and single 
HMO standard. 
 
(a) 
  
 
(b) 
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(c) 
  
 
(d) 
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(f) 
  
 
(g) 
  
Figure 4-17 Analysis of metabolic products from B. infantis grown in Bifidobacterium 
medium on different carbon substrates. (a) Glucose (left) and galactose (right). (b) Lactose 
(left) and the neutral HMO fractions from LeA3 (right). (c) Acidic HMO fractions from LeA3 (left) 
and neutral HMO fractions from LeB2 (right). (d) Acidic HMO fractions from LeA2 (left) and 
neutral HMO fractions from Le0 (right). (e) Acidic HMO fraction from Le0 (left) and HMO 
standard 2’-FL (right). (f) HMO standard 3-FL (left) and HMO standard LNT (right). (g) HMO 
standard LNnT (left) and 6’-SL (right). 
 
The chromatograms above from HPLC showed that B. infantis could metabolize 
the carbon substrates and produce mainly lactic acid, acetic acid, and some formic 
acid. The amount of glucose showed that the initial amount of glucose were from 3 to 
7 mM, and glucose can be metabolized within 15 hours, and for most carbon 
substrates, the amount of glucose stayed at 0 mM until the end, except the case for 
6’-SL, the glucose increased to 2 mM after 15hours. For the product lactate, the initial 
amount was between 3 and 4 mM, and in the first 15hours, it showed an increase for 
all the carbon substrates. After 15 hours, most carbon substrates showed a 
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continuously increase by a lower increase rate. The exception occurred for the acidic 
HMO fractions from LeA3, the lactate was decreased. The amount of lactate in the 
end was mostly around 9 mM, and ranged up to about 19 mM. For the product 
formate, the initial amount was from 3 to 10 mM. About half of the carbon substrates 
showed an increase in the first 15 hours, two of the substrates showed a decrease, 
and the rest showed nearly the same. After 15 hours, most carbon substrates stayed 
the same and only four of them showed an increase, the rest stayed almost the same. 
The amount of formate in the end was around 9 mM. For the product acetate, the 
initial amount was from 3 to 8 mM. The amount of acetate showed an increase for all 
the carbon substrates in the first 15hours. For most carbon substrates, the amount of 
acetate reached to 14 to 20 mM. Only one of the carbon substrates was lower: the 
amount of 6’-SL was 12 mM and two of them were higher than 20 mM: the amount 
from LNT was about 23 mM and the amount from LNnT was about 37 mM. After 15 
hours, the amount showed also a continuously increase for all the carbon substrate, 
but with a lower increase rate. The final amount of acetate was from 19 to 25 mM, with 
the exception of 6’-SL and LNnT. The amount from 6’-SL was 16 mM and the amount 
from LNnT was 25 mM. 
 
(a) 
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(b) 
  
(c) 
  
(d) 
  
(e) 
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(f) 
  
(g) 
  
Figure 4-18 Analysis of metabolic products from B. longum grown in Bifidobacterium 
medium on different carbon substrates. (a) Glucose (left) and galactose (right). (b) Lactose 
(left) and neutral HMO fractions from LeA3 (right). (c) Acidic HMO fractions from LeA3 (left) 
and neutral HMO fractions from LeB2 (right). (d) Acidic HMO fractions from LeA2 (left) and 
neutral HMO fractions from Le0 (right). (e) Acidic HMO fraction from Le0 (left) and HMO 
standard 2’-FL (right). (f) HMO standard 3-FL (left) and HMO standard LNT (right). (g) HMO 
standard LNnT(left) and 6’-SL (right). 
 
 
The chromatograms from HPLC showed that B. longum could also metabolic 
the carbon substrates and produce mainly lactic acid, acetic acid, and some formic 
acid. The amount of glucose showed that the initial amount of glucose were also from 
3 to 8 mM. Glucose can be metabolized within 15 hours for most of the carbon 
substrates and stayed at 0 mM until the end. The exception occurred for the acidic 
HMO fraction from LeA3 and the neutral HMO fraction from LeB2, glucose was not 
metabolized within 15 hours, but the amount of glucose was also 0 mM in the end. For 
the product lactate, the initial amount was between 3 and 5 mM, and in the first 15 
hours, it showed an increase for all the carbon substrates, increased by 2 to 5 mM. 
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After 15 hours, nine of the carbon substrates showed a continuously increase, in 
which one of carbon substrates increased by a higher increase rate, two of carbon 
substrates showed a lower increase rate, and the rest increase by the same increase 
rate. One of the carbon substrates showed a decrease after 15 hours and the rest 
stay the same after 15 hours. The amount of lactate in the end ranged from 5 to 15 
mM. For the product formate, the initial amount was mostly around 5 mM, with three 
exceptions. Most of the carbon substrates showed an increase in the first 15 hours, 
three of the substrates showed a decrease, and the rest showed nearly the same. 
After 15 hours, seven of the carbon substrates showed a continuously increase and 
the rest stayed almost the same amount. The amount of formate in the end was 
around 10 mM, except the amount from LNT, about 17 mM. For the product acetate, 
the initial amount was from 4 to 10 mM. The amount of acetate showed an increase 
for all the carbon substrate in the first 15hours, the same as B. infantis. For most 
carbon substrates, the amount of acetate reached to 13 to 16 mM. Only three of the 
carbon substrates were around 10 mM: the amount of galactose, the neutral HMO 
fraction from LeB2 and the single standard 6’-SL. Three of them were about 20 mM: 
the amount of glucose, the neutral HMO fraction from LeA3 and the single standard 
LNT. The highest one was from lactose, reached up to 24 mM. After 15 hours, the 
amount showed also a continuously increase for all the carbon substrates, in which 
one of them showed a higher increase rate, three of them showed the same increase 
rate, and the rest showed a lower increase rate. The final amount of acetate ranged 
from 13 to 32 mM, in which galactose was about 13 mM, was the lowest, glucose was 
about 24 mM. Four of them were around 30 mM: lactose, neutral HMO fractions from 
LeA3, the single standard LNT and LNnT. The rest were around 19 mM, from 16 mM 
to 22 mM.
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5 Discussion 
5.1 Isolation of HMO fractions from human milk 
Neutral and acidic HMO fractions were isolated from six human milk samples. In 
principle, from the whole HMO fractions, about 2/3 of the whole HMO fractions are 
neutral, about 1/3 are acidic. As shown in Table 4-1, the amounts of neutral HMO 
fractions from 50 ml human milk was 80 or 110 mg; the amounts of neutral HMO 
fractions from 100 ml human milk were from 170 to 274 mg, which were double values 
from 50 ml human milk, with some fractions higher. In principle, the amounts of acidic 
HMO fractions would be half of the neutral HMO fractions. But the values from HMO 
fractions were higher than half neutral fractions, and for LeA2, the amount of acidic 
fractions were higher than neutral fractions. The reasons for higher neutral and acidic 
fractions could be the following: first, the procedure of isolation from human milk were 
complex, there might be still some other components left in the neutral HMO fractions, 
such as lactose; second, the desalting of acidic HMO fractions were not that accurate, 
so that there were still some salts left; third, the acidic HMO fractions contained not 
only acidic HMOs, but also some other acidic fractions. The results indicated that the 
purity of the isolated HMO fractions were not as high as the single HMO standards, it 
could also explain the later results in microorganisms study. 
 
 
5.2 Growth study of microorganisms on glucose, galactose and 
lactose 
The growth study of L. acidophilus on glucose, galactose and lactose showed 
that the highest OD500nm without carbon substrate was about 0.2. The value with 1 mM 
glucose or galactose was about 0.3, the difference from the value without carbon 
substrate was about 0.1. The values with 2 mM glucose, 2 mM galactose or 1 mM 
lactose were about 0.4, the difference from the value without carbon substrate was 
about 0.2. Thus, when the amount of glucose or galactose was doubled, the 
difference was also doubled. The value with 1 mM lactose was similar to 2 mM 
glucose or galactose. The reason is that 1 mol lactose can be hydrolyzed into 1 mol 
glucose and 1 mol galactose. The value with 2 mM lactose was about 0.6, the 
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difference from the value without carbon substrate was about 0.4, the difference was 
also doubled when the amount of lactose was doubled. 
The growth study of L. lactis on glucose, galactose and lactose showed that the 
highest OD500nm without carbon substrate was about 0.4. The value with 1 mM 
glucose was about 0.55 and the value with 1 mM galactose was about 0.5. The 
reason could be the structure difference of glucose and galactose, L. lactis couldn’t 
utilize the galactose as well as glucose. The highest OD500nm with 2 mM glucose was 
about 0.7; the difference from the value without carbon substrate was doubled 
compared with 1 mM glucose. The value with 2 mM galactose was reduced to about 
0.45, and the value with 5 mM galactose was similar to 2 mM galactose. The results 
showed that the high concentration of galactose could inhibit the growth of L. lactis. 
The reason may be that the galactose had the feedback inhibition. The highest 
OD500nm with 1 mM lactose was about 0.65, the value with 2 mM lactose was about 
0.45 and the value with 5 mM lactose was about 0.5. The reason could be that when 
the concentration of lactose was 2 mM, the inhibit effect of galactose was dominant. 
When the concentration of lactose increased to 5 mM, there may be more glucose 
hydrolyzed and the growth increased a little bit.  
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5.3 Growth study of microorganisms on HMO fractions and HMO 
standard 
5.3.1 Lactococcus lactis subsp. lactis 
 
Figure 5-1(a) Comparison of the highest OD500nm (Mean ± SD, n=3) of L. lactis grown in 
MRS medium (without glucose) with different substrates. The dark columns show the 
neutral saccharides, including the 1 mM glucose, 1 mM galactose, 1 mM lactose, and six 
different neutral HMO fractions, four kinds of neutral single HMO standards. The light columns 
show 0 mM glucose (for control) and the acidic saccharides, including the six different acidic 
HMO fractions and one kind of single acidic HMO standard. 
 
From Figure 5-1(a), the highest OD500nm from different substrate utilized by L. 
lactis can be compared. The OD500nm without carbon substrate was the lowest. The 
highest OD500nm with the two kinds of mono-saccharide, glucose and galactose, were 
higher, because glucose and galactose can supply carbon substrate to the bacteria. 
The OD500nm of lactose, which belongs to di-saccharide, was even higher, because 1 
mol lactose contains 1 mol glucose and 1mol galactose. The HMO fractions are the 
mixture of oligosaccharides with different DP (the degree of polymerization, DP ≥3), 
the highest OD500nm of the six kinds of neutral HMO fractions were mostly higher than 
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the OD500nm from lactose with the exception of LeA2n. The highest OD500nm for the 
acidic HMO fractions showed general lower values compared with the corresponding 
neutral fractions. The reason may be the different components from neutral and acidic 
HMO fractions, the neutral HMO fractions have a similar pH values to the medium (pH 
6.0 to 6.5), while the acidic HMO fractions have lower pH, which may decrease the pH 
value of the medium and thereby affect to low pH for optimal growth of bacteria. 
Another possible reason was that there may be some other component in the acidic 
HMO fractions, it is not pure acidic HMO, but contained some other acidic substrates, 
like some salts and so on. The salt may be inhibitory for the growth. The highest 
OD500nm from the five single HMO standards were similar to lactose, in which the 
OD500nm from LNnT was lower and the OD500nm from 6’-SL was higher. The 2’-FL and 
3-FL are the tri-saccharides, and the LNT and LNnT are tetra-saccharides. In principle, 
the tri-saccharides contain three monosaccharides, but L. lactis may not contain all 
the enzymes to hydrolyze tri-saccharides to the monosaccharide. For the 
tetra-saccharides, the reason was the same. The reason why the LNnT was lower 
could be that the LNnT is the new pattern of LNT, which may contains different bond 
from LNT, and then the L. lactis may utilize LNT better than LNnT. From the 
comparison of the HMO fractions with Lewis a, Lewis b and Lewis 0 specificity, there 
was no distinct difference between the Lewis patterns. The highest OD500nm of the 
HMO fractions from LeA1, LeA3, LeB2 and Le0 were similar. The bacteria didn’t grow 
well on HMO fractions from LeA2 and LeB1, especially the neutral fractions from 
LeA2, even lower than the acidic fractions from LeA2. The reason may be that the 
number of samples for each Lewis group was too small to represent a group of 
fractions. Another reason could be that the individual differences from each milk 
sample since, the donate mothers were distinct from each other.  
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Figure 5-1(b) Comparison of the growth rate (h-1) from L. lactis grown in MRS medium 
(without glucose) with different substrates. The dark columns show the neutral 
saccharides, including the 1 mM glucose, 1 mM galactose, 1 mM lactose, and six different 
neutral HMO fractions, four kinds of neutral single HMO standards. The light columns show 0 
mM glucose (for control) and the acidic saccharides, including the six different acidic HMO 
fractions and one kind of single acidic HMO standard. 
 
The growth rate, which reflects the growth speed of the microorganisms, is 
another important factor to describe growth of the microorganisms. It describes the 
increase of OD500nm per time unit. From the Figure 5-1(b), the growth rate from L. lactis 
grown on different substrates can be compared. Without any carbon substrate, the 
growth rate was about 0.06, was also the lowest compared with other substrates. The 
reason is the limited amount of carbon substrate. The growth rates from HMO 
fractions were mostly from 0.07 to 0.09, except the growth rate from the Le0n sample, 
which reached to about 0.11. The growth rates from the five single HMO standards 
were almost higher than those from the HMO fractions. The reason may be related to 
the purity of the HMOs, the single HMO standards were with higher purity compared 
with the HMO fractions.  
From the results combined with the highest OD500nm and the growth rate, the 
following conclusions can be drawn: lactose, neutral fractions from LeA1, neutral and 
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acidic fraction from LeA3, neutral fractions from LeB2, 3-FL, LNT and 6’-SL were 
substrates which seem to have beneficial effect on the growth of L. lactis.  
 
5.3.2 Lactobacillus acidophilus 
 
Figure 5-2(a) Comparison of the highest OD500nm (Mean ± SD, n=3) of L. acidophilus 
grown in MRS medium plus L-cysteine (without glucose) with different substrates. The 
dark columns show the neutral saccharides, including the 1 mM glucose, 1 mM galactose, 1 
mM lactose, and six different neutral HMO fractions, four kinds of neutral single HMO 
standards. The light columns show 0 mM glucose (for control) and the acidic saccharides, 
including the six different acidic HMO fractions and one kind of single acidic HMO standard. 
 
From Figure 5-2(a), the highest OD500nm from different substrates utilized by L. 
acidophilus can be compared. The highest OD500nm without carbon substrate, glucose, 
galactose and lactose were similar to L. lactis. The highest OD500nm of the five kinds of 
neutral HMO fractions were all higher than the values from lactose and the 
corresponding acidic HMO fractions. The highest OD500nm from the single HMO 
standard 2’-FL, LNT and 6’-SL showed the highest OD500nm compared with all the 
other substrates. The highest OD500nm of single HMO standards 3-FL and LNnT were 
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between glucose and lactose. The reason could be the structure difference from 2’-FL 
and 3-FL, LNT and LNnT. The bacteria may secrete the enzyme that can hydrolyze 
the chemical bonds in 2’-FL and LNT, but fewer bonds in 3-FL and LNT can be 
hydrolyzed. From the comparison of the HMO fractions with different Lewis specificity, 
the values from the six HMO fractions were all similar. Not only on distinct from 
different Lewis pattern, but also not distinct from different HMO fractions with the 
same Lewis specificity. 
 
 
Figure 5-2(b) Comparison of the growth rate (h-1) from L. acidophilus grown in MRS 
medium plus L-cysteine (without glucose) with different substrates. The dark columns 
show the neutral saccharides, including the 1 mM glucose, 1 mM galactose, 1 mM lactose, 
and six different neutral HMO fractions, four kinds of neutral single HMO standards. The light 
columns show 0 mM glucose (for control) and the acidic saccharides, including the six different 
acidic HMO fractions and one kind of single acidic HMO standard. 
 
From Figure 5-2(b), the growth rate from L. acidophilus grown on different 
substrates can be compared. Without any carbon substrate, the growth rate is about 
0.12, was also the lowest compared with other substrates. The growth rates of 
glucose and galactose were around 0.14, and the growth rate of lactose was about 
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0.16. The growth rates from HMO fractions were mostly higher than glucose and 
galactose, between 0.16 and 0.18, except the growth rate from LeB1a sample, which 
was about 0.13. The growth rates from neutral fractions were all higher than the 
corresponding acidic fractions. The growth rates from the five single HMO standards 
had the similar values from HMO fractions.  
From the results combined with the highest OD500nm and the growth rate, the 
following conclusions can be drawn: lactose, neutral fractions from LeA1, LeA2, LeA3, 
LeB1, LeB2, acidic fraction from LeA1, LeB2 and single standard 2’-FL, 3-FL and 
6’-SL were substrates which seem to have beneficial effect on the growth of L. 
acidophilus.  
 
5.3.3 Bifidobacterium longum subsp. infantis 
 
Figure 5-3(a) Comparison of the highest OD500nm (Mean ± SD, n=3) of B. infantis grown 
in Bifidobacterium medium (without glucose) with different substrates. The dark 
columns show the neutral saccharides, including the 1 mM glucose, 1 mM galactose, 1 mM 
lactose, and six different neutral HMO fractions, four kinds of neutral single HMO standards. 
The light columns show 0 mM glucose (for control) and the acidic saccharides, including the 
six different acidic HMO fractions and one kind of single acidic HMO standard. 
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From Figure 5-3(a), the highest OD500nm from different substrates utilized by B. 
infantis can be compared. The highest OD500nm of the six kinds of neutral HMO 
fractions were all higher than that of glucose, in which three of them were higher than 
that of lactose. The highest OD500nm from neutral HMO fractions were between 0.8 and 
0.9, the values from the acidic HMO fractions were between 0.6 and 0.8. The highest 
OD500nm of the five single HMO standards showed that they were all higher than those 
of glucose and galactose, but only the OD500nm of LNT was higher than lactose. The 
highest OD500nm of 6’-SL was the lowest among the five. The reason could be that it is 
acidic HMO standard. From the comparison of the HMO fractions with different Lewis 
specificity, there were no difference from Lewis a, Lewis b and Lewis 0 pattern. The 
results seem to be different from individual HMO samples, but not depending on the 
Lewis blood type. 
 
 
Figure 5-3(b) Comparison of the growth rate (h-1) from B. infantis grown in 
Bifidobacterium medium (without glucose) with different substrates. The dark columns 
show the neutral saccharides, including the 1 mM glucose, 1 mM galactose, 1 mM lactose, 
and six different neutral HMO fractions, four kinds of neutral single HMO standards. The light 
columns show 0 mM glucose (for control) and the acidic saccharides, including the six different 
acidic HMO fractions and one kind of single acidic HMO standard. 
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From Figure 5-3(b), the growth rate from B. infantis grown on different substrates 
can be compared. The growth rates from the six neutral HMO fractions were between 
0.05 and 0.06, while the growth rates from the six acidic HMO fractions were all lower 
than the corresponding neutral fractions, and the values were around 0.05. The 
growth rates from the five single HMO standards ranged from 0.049 to 0.059. The 
growth rates from 2’-FL and LNT were similar, the value from 3-FL was higher and the 
value from LNnT was lower. The reason may be that the bacteria prefer the structure 
of 3-FL rather than 2’-FL, and the structure of LNnT was more difficult than LNT for 
the bacteria to metabolize. 
From the results combined with the highest OD500nm and the growth rate, the 
following conclusions can be drawn: lactose, neutral fractions from LeA1, LeA3, LeB2, 
and Le0, acidic fraction from LeB2 and single standard 3-FL and LNT were substrates 
which seem to have beneficial effect on the growth of B. infantis.  
 
5.3.4 Bifidobacterium longum subsp. infantis vs. Bifidobacterium 
longum subsp. longum 
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Figure 5-4(a) Comparison of the highest OD500nm (Mean ± SD, n=3) of the growth from B. 
infanis vs. B. longum grown in Bifidobacterium medium (without glucose) with 
different substrates. The dark columns show the neutral saccharides, including the 1 mM 
glucose, 1 mM galactose, 1 mM lactose, and six different neutral HMO fractions, four kinds of 
neutral single HMO standards. The light columns show 0 mM glucose (for control) and the 
acidic saccharides, including the five different acidic HMO fractions and one kind of single 
acidic HMO standard. 
 
From Figure 5-4(a), the highest OD500nm from different substrates utilized by B. 
infantis and B. longum can be compared. For all the carbon substrates, the values 
from B. infantis were higher than the corresponding values from B. longum. The 
highest OD500nm without substrates for both bacteria were the lowest compared with 
other carbon substrates. For the substrates glucose, galactose, lactose and six kinds 
of HMO fractions, the OD500nm differences of both bacteria were similar, mostly about 
0.2. For the 5 kinds of single standard, the OD500nm differences between the two 
bacteria were smaller, mostly about 0.1.  
  
 
Figure 5-4(b) Comparison of the growth rate (h-1) from B. infantis vs. B. longum grown 
in Bifidobacterium medium (without glucose) with different substrates. The dark 
columns show the neutral saccharides, including the 1 mM glucose, 1 mM galactose, 1 mM 
lactose, and six different neutral HMO fractions, four kinds of neutral single HMO standards. 
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The light columns show 0 mM glucose (for control) and the acidic saccharides, including the 
six different acidic HMO fractions and one kind of single acidic HMO standard. 
From Figure 5-4(b), the growth rate from B. infantis and B. longum grown on 
different substrates can be compared. For all the carbon substrates, the values from B. 
infantis were mostly higher than the corresponding values from B. longum with only 
two exceptions: HMO fractions from Le0a and the single standard LNnT. The growth 
rate without substrates for B. longum was the lowest compared with other carbon 
substrates, and the value for B. infantis was similar to the values from HMO fractions 
from LeA3a, Le0a, and single standard LNnT.  
From the results combined with the highest OD500nm and the growth rate, the 
following conclusions can be drawn: the growths of B. infantis on all the carbon 
substrates were better the growth of B. longum. 
 
5.3.5 Bacteroides vulgatus 
 
Figure 5-5(a) Comparison of the highest OD500nm (Mean ± SD, n=3) of B. vulgatus grown 
in Modified Reinforced Clostridial Broth (without glucose) with different substrates. 
The dark columns show the neutral saccharides, including the 1 mM glucose, 1 mM galactose, 
1 mM lactose, and six different neutral HMO fractions, four kinds of neutral single HMO 
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standards. The light columns show 0 mM glucose (for control) and the acidic saccharides, 
including the six different acidic HMO fractions and one kind of single acidic HMO standard. 
From Figure 5-5(a), the highest OD500nm from different substrates utilized by B. 
vulgatus can be compared. The highest OD500nm of the six kinds of neutral HMO 
fractions were higher than that of glucose or galactose, in which five of them were 
higher than that of lactose. The highest OD500nm from neutral HMO fractions were 
mostly higher than the corresponding acidic HMO fractions with the exception of LeA3. 
The highest OD500nm of the four kinds of neutral single HMO standards were all higher 
than those of glucose and galactose, in which three of them were higher than that of 
lactose, except 3-FL. The value from the acidic single standard 6’-SL was similar to 
glucose and galactose. From the comparison of the neutral HMO fractions with Lewis 
a, Lewis b and Lewis 0 specificity, there was no distinct difference between the Lewis 
patterns. From the comparison of the acidic HMO fractions with Lewis a, Lewis b and 
Lewis 0 specificity, the values from LeA were around 0.7, the values from LeB were 
between 0.5 and 0.6, the value from Le0 was about 0.8. From the results, it seems 
that the acidic fraction from Le0 was the best for the growth of bacteria, while the 
acidic fractions from LeB were not as good as the other two Lewis pattern. 
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Figure 5-5(b) Comparison of the growth rate (h-1) from B. vulgatus grown in Modified 
Reinforced Clostridial Broth (without glucose) with different substrates. The dark 
columns show the neutral saccharides, including the 1 mM glucose, 1 mM galactose, 1 mM 
lactose, and six different neutral HMO fractions, four kinds of neutral single HMO standards. 
The light columns show 0 mM glucose (for control) and the acidic saccharides, including the 
six different acidic HMO fractions and one kind of single acidic HMO standard. 
 
From Figure 5-5(b), the growth rate from B. vulgatus grown on different 
substrates can be compared. The growth rates from the six neutral HMO fractions 
were around 0.075, which were all a little bit higher than glucose, galactose and 
lactose, while the growth rates from the six acidic HMO fractions were all lower than 
the corresponding neutral HMO fractions, the values were from 0.065 to 0.072. The 
growth rates from the five single HMO standards were from 0.067 to 0.082. The 
growth rates from 2’-FL and 3-FL were around 0.07, the value from 2’-FL was higher 
than 3-FL, the reason may be that the bacteria prefer to metabolize the structure of 
2’-FL. The growth rates from LNT and LNnT were similar, both about 0.08. The growth 
rate from 6’-SL was about 0.07.  
From the results combined with the highest OD500nm and the growth rate, the 
following conclusions can be drawn: lactose, neutral fractions from LeA1, LeA2, LeB1, 
LeB2, LeB2 and Le0, acidic fractions from Le0, single standard 2’-FL, LNT and LNnT 
were substrates which seem to have beneficial effect on the growth of B. vulgatus.  
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5.3.6 Cronobacter sakazakii 
 
Figure 5-6(a) Comparison of the highest OD500nm (Mean ± SD, n=3) of C. sakazakii grown 
in MRS medium (without glucose) with different substrates. The dark columns showed 
the neutral saccharides, including the 1 mM glucose, 1 mM galactose, 1 mM lactose, and six 
different neutral HMO fractions, four kinds of neutral single HMO standard. The light columns 
showed 0 mM glucose (for control) and the acidic saccharides, including the six different acidic 
HMO fractions and one kind of single acidic HMO standard. 
 
From Figure 5-6(a), the highest OD500nm from different substrates utilized by C. 
sakazakii can be compared. The OD500nm without carbon substrate was about 0.75, 
was the lowest. The highest OD500nm with glucose and galactose, were higher, around 
0.9. The OD500nm of lactose reached to about 1.1, was the highest from all the 
substrates. The highest OD500nm of the six kinds of neutral HMO fractions were 
between 0.8 and 1.1, in which two of them were about 0.85, three of them were 
around 1.0, and the value from LeA1 was similar to lactose. The highest OD500nm from 
acidic HMO fractions were all lower than the corresponding neutral HMO fractions, in 
which five of them were around 0.8, only a little bit higher than the value without 
carbon substrates. That means the bacteria didn’t utilize the most acidic HMO 
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fractions. The highest OD500nm of the five kinds of single HMO standards were 
between 0.8 and 0.95, in which 2’-FL, LNnT and 6’-SL were about 0.8, this represent 
that the bacteria didn’t utilize the three substrates. From the comparison of the HMO 
fractions with Lewis a, Lewis b and Lewis 0 specificity, there was no distinct difference 
between the Lewis patterns. 
 
 
Figure 5-6(b) Comparison of the growth rate (h-1) from C. sakazakii grown in MRS 
medium (without glucose) with different substrates. The dark columns showed the neutral 
saccharides, including the 1 mM glucose, 1 mM galactose, 1 mM lactose, and six different 
neutral HMO fractions, four kinds of neutral single HMO standard. The light columns showed 0 
mM glucose (for control) and the acidic saccharides, including the six different acidic HMO 
fractions and one kind of single acidic HMO standard. 
From Figure 5-6(b), the growth rate from C. sakazakii grown on different 
substrates can be compared. The growth rate without carbon substrate was about 
0.085, was not the lowest compared with all the substrates. The growth rate with 
glucose was about 0.095, was the highest among all the substrate. The value with 
galactose was about 0.08, lower than without carbon substrate. The value with 
lactose was about 0.09. The growth rates from the six neutral HMO fractions were 
around 0.085, which were similar to lactose. The growth rates from the six acidic HMO 
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fractions were between 0.07 and 0.08, were all lower than the corresponding neutral 
HMO fractions and the value without carbon substrate. The values also indicate the 
similar results from the highest OD500nm; the bacteria didn’t utilize the acidic HMO 
fractions. The growth rates from the five single HMO standards were from 0.08 to 
0.095, in which LNT, LNnT and 6’-SL were about 0.08, 2’-FL was about 0.085, similar 
to no carbon substrate. 3-FL was the highest, about 0.095. The reason may be that 
2’-FL, LNT, LNnT and 6’-SL were no the growth substrate, and may inhibit the growth 
of the bacteria.  
From the results combined with the highest OD500nm and the growth rate, the 
following conclusions can be drawn: glucose, lactose and 3-FL were substrates which 
seem to have beneficial effect on the growth of C. sakazakii. The acidic HMO fractions 
from LeA2, LeA3, LeB1, LeB2 and Le0, the single standard 2’-FL, LNT, LNnT and 
6’-SL were substrates which seem to have no effect or inhibit effect on the growth of C. 
sakazakii.  
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5.3.7 Akkermansia muciniphila 
 
Figure 5-7(a) Comparison of the highest OD500nm (Mean ± SD, n=3) of the growth from A. 
muciniphila grown in Modified Reinforced Clostridial Broth (without glucose) with 
different substrates. The dark columns showed the neutral saccharides, including the 1 mM 
glucose, 1 mM galactose, 1 mM lactose, and six different neutral HMO fractions, four kinds of 
neutral single HMO standard. The light columns showed 0 mM glucose (for control) and the 
acidic saccharides, including the six different acidic HMO fractions and one kind of single 
acidic HMO standard. 
 
From Figure 5-7(a), the highest OD500nm from different substrates utilized by A. 
muciniphila can be compared. The highest OD500nm without carbon substrate was 
about 0.5, was the lowest. The highest OD500nm with glucose and galactose, were 
higher, between 0.7 and 0.8. The OD500nm of lactose was even higher, about 0.85. The 
highest OD500nm of the six kinds of neutral HMO fractions were between 0.7 and 0.95, 
in which three of them were above 0.9, higher than lactose, one of them was about 
0.8, was lower than glucose. The highest OD500nm from acidic HMO fractions were 
from 0.6 to 0.75, all lower than glucose and the corresponding neutral HMO fractions. 
The highest OD500nm of the five kinds of single HMO standards were between 0.6 and 
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0.8, in which 2’-FL and 3-FL were about 0.6, LNT and LNnT were around 0.8. The 
reason may be that the bacteria prefers the structure of LNT and LNnT than 2’-FL and 
3-FL. The value of 6’-SL was about 0.65. From the comparison of the HMO fractions 
with Lewis a, Lewis b and Lewis 0 specificity, there was no distinct difference between 
the Lewis patterns. For the neutral HMO fractions, the values of the two Lewis b seem 
to have benefit effect compared with most other Lewis patterns. For the acidic HMO 
fractions, the values from the all the six samples were similar. 
 
 
Figure 5-7(b) Comparison of the growth rate (h-1) of the growth from A. muciniphila 
grown in Modified Reinforced Clostridial Broth (without glucose) with different 
substrates. The ark columns showed the neutral saccharides, including the 1 mM glucose, 1 
mM galactose, 1 mM lactose, and six different neutral HMO fractions, four kinds of neutral 
single HMO standard.The light columns showed 0 mM glucose (for control) and the acidic 
saccharides, including the six different acidic HMO fractions and one kind of single acidic HMO 
standard. 
 
From Figure 5-7(b), the growth rate from A. muciniphila grown on different 
substrates can be compared. The growth rate without carbon substrate was about 
0.05, was not the lowest compared with all the substrates. The growth rate with 
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glucose and galactose were nearly the same, about 0.057. The value with lactose 
was about 0.07, was the highest among all the substrates. The growth rates from the 
six neutral HMO fractions ranged from 0.053 to 0.068, in which three of them were 
about 0.065, higher than glucose and galactose, one of them was about 0.068, similar 
to lactose. The growth rates from the six acidic HMO fractions were all lower than the 
corresponding neutral HMO fractions, mostly between 0.05 and 0.06, with exception 
of LeA1, which was only about 0.045, was the lowest among all the substrate. The 
growth rates from the five single HMO standards were from 0.05 to 0.062, in which 
2’-FL and 3-FL were about 0.05, LNT and LNnT were about 0.055, 6’-SL was the 
highest, about 0.62, higher than the values from glucose and galactose.  
From the results combined with the highest OD500nm and the growth rate, the 
following conclusions can be drawn: glucose, lactose, neutral HMO fractions from 
LeA2, LeA3, LeB1, LeB2 and Le0, the single standard LNT and LNnT were substrates 
which seem to have beneficial effect on the growth of A. muciniphila.  
 
5.3.8 Comparison of ΔOD from different microorganisms 
In order to compare the effects of different carbon substrates on the growth of 
different microorganisms, ΔOD from the highest OD500nm on different carbon 
substrates and the highest OD500nm without carbon substrate were evaluated. Table 
5-1 shows the highest OD500nm and ΔOD from without and with different carbon 
substrates on different microorganisms. For easier comparison, the substrates were 
divided into four groups: the first group contained mono- and di-saccharides, the 
second group was the neutral HMO fractions, the third group was the acidic HMO 
fractions, and the last group was the single HMO standards. For all the seven bacteria, 
the results from the first group of different microorganisms were similar. The ΔOD 
values from glucose and galactose were mostly ++, only the values from B. longum 
were +. The values from lactose were from +++ to ++++, with the exception of C. 
sakazakii. The results from the second group showed that the carbon substrates 
LeA1n, LeA3n, LeB2n and Le0 had beneficial effects on most of the microorganisms. 
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The results from the third group showed that the acidic HMO fractions didn’t have 
beneficial effects on microorganism as neutral HMO fractions. The values from LeA1a, 
LeA3a and LeB2a had relatively better effects than the other carbon substrates. The 
results from the last group showed that 3-FL and LNT had beneficial effects on most 
of the microorganisms. From the comparison of seven microorganisms, the results 
showed that most HMO fractions and single HMO standards had beneficial effects L. 
lactis, L. acidophilus, B. infantis and B. vulgatus. For A. muciniphila, lactose and the 
neutral HMO fractions had beneficial effects, but the acidic HMO fractions and most 
single HMO standards didn’t have beneficial effects. For B. longum and C. sakazakii, 
only lactose, few of HMO fractions showed beneficial effects.
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Table 5-1 The highest OD500nm and ΔOD from without and with different carbon substrates on different microorganisms 
 L. 
lactis 
ΔOD L. 
acidophilus 
ΔOD B. 
infantis 
ΔOD B. 
longum 
ΔOD B. 
vulgatus 
ΔOD C. 
sakazakii 
ΔOD A. 
muciniphila 
ΔOD 
0 mM Glc 0.410   0.356   0.578   0.497   0.462   0.744   0.511   
1 mM Glc 0.592  ++ 0.542  ++ 0.751  ++ 0.630  + 0.626  ++ 0.899  ++ 0.784  +++ 
1 mM Gal 0.554  ++ 0.458  + 0.722  ++ 0.595  + 0.667  +++ 0.879  ++ 0.706  ++ 
1 mM Lac 0.653  +++ 0.616  +++ 0.920  ++++ 0.701  +++ 0.745  ++++ 1.117  ++++
+ 
0.848  ++++ 
               
1 mM LeA1n 0.850  ++++++ 0.657  ++++ 0.974  ++++
+ 
0.969  ++++
++ 
0.813  ++++ 1.103  ++++ 0.716  +++ 
1 mM LeA2n 0.509  + 0.658  ++++ 0.787  ++ 0.652   0.798  ++++ 0.972  +++ 0.812  ++++ 
1 mM LeA3n 0.805  ++++ 0.647  ++++ 0.952  ++++
+ 
0.688  ++ 0.691  +++ 1.016  +++ 0.895  ++++
+ 1 mM LeB1n 0.679  +++ 0.639  ++++ 0.826  ++ 0.826  ++++ 0.786  ++++ 0.874  ++ 0.892  +++
+ 1 mM LeB2n 0.858  ++++++ 0.669  ++++ 0.938  ++++
+ 
0.643  ++ 0.811  ++++ 1.014  +++ 0.940  +++
+ 1 mM Le0n 0.862  ++++++ 0.635  +++ 0.877  +++ 0.666  ++ 0.876  ++++
+ 
0.863  ++ 0.809  +++ 
               
1 mM LeA1a 0.776  +++++ 0.599  +++ 0.798  +++ 0.798  ++++ 0.696  +++ 0.939  ++ 0.627  + 
1 mM LeA2a 0.612  +++ 0.550  ++ 0.628  + 0.573  + 0.663  +++ 0.791  + 0.676  ++ 
1 mM LeA3a 0.738  ++++ 0.560  +++ 0.832  +++ 0.611  + 0.729  +++ 0.833  + 0.617  + 
1 mM LeB1a 0.562  ++ 0.531  ++ 0.674  + 0.674  ++ 0.532  + 0.785  + 0.678  ++ 
1 mM LeB2a 0.708  +++ 0.604  +++ 0.827  +++ 0.562  + 0.589  ++ 0.833  + 0.733  +++ 
1 mM Le0a 0.631  +++ 0.573  +++ 0.714  ++ 0.625  ++ 0.769  ++++ 0.777  +/- 0.651  ++ 
               
1 mM 2'-FL 0.620  +++ 0.699  ++++ 0.804  +++ 0.671  ++ 0.836  ++++
+ 
0.804  + 0.623  + 
1 mM 3-FL 0.743  ++++ 0.582  +++ 0.884  ++++ 0.749  +++ 0.729  ++ 0.962  +++ 0.641  ++ 
1 mM LNT 0.654  +++ 0.687  ++++ 0.940  ++++
+ 
0.697  +++ 0.797  ++++ 0.867  ++ 0.817  ++++ 
1 mM LNnT 0.511  + 0.553  ++ 0.826  ++ 0.671  ++ 0.884  ++++
+ 
0.816  + 0.749  +++ 
1 mM 6'-SL 0.823  +++++ 0.686  ++++ 0.771  ++ 0.564  + 0.644  + 0.766  +/- 0.665  ++ 
Note: +/-: <0.04; +: ≥0.04 and <0.12; ++: ≥0.12 and <0.20; +++: ≥ 0.20 and < 0.28; ++++: ≥ 0.28 and <0.36; +++++: ≥0.36 and < 0.44; +++++: ≥ 0.44 and < 0.52. 
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5.3.9 Effect of HMOs on growth of microorganisms in comparison to 
previous studies 
Human milk oligosaccharides have been considered to be beneficial for growth of 
infants’ intestinal microorganisms for a long time. Recently, scientists used in vitro 
studies to investigate the effect of HMOs on intestinal microorganisms. In many 
studies the focus was on proofing the beneficial effects of HMOs on the growth of 
Bifidobacteria, especially B. infantis (Chichlowski et al., 2011). In further studies other 
Bifidobacteria species, such as B. longum, B. breve, B. bifidum, B. adolescentis were 
used (Ward et al., 2007). In addition, some other intestinal microorganisms, such as L. 
lactis, L. acidophilus, L. gasseri (Lactobacillus gasseri), E. coli, S. thermophiles 
(Streptococcus thermophilus), B. vulgatus, B. fragilis (Bacteroides fragilis) (Marcobal 
et al., 2010; Ward et al., 2004) were also studied for growth effects of HMOs. The 
carbon substrates for the studies were the whole HMO fractions. Glucose, galactose, 
lactose, or some specific oligosaccharides, such as GOS, FOS, arabino- 
oligosaccharides have also been studied for comparison of effects on microorganisms 
although the latter oligosaccharides are not a component of human milk. 
L. acidophilus and L. lactis are considered as very important intestinal 
microorganisms in infants. The study from Marcobal et al. (2010) showed that L. lactis 
grew on HMOs with ΔOD600nm of 0.124, and L. acidophilus grew on HMOs with 
ΔOD600nm of 0.290 in the chemical ZMB medium. In our study, the medium for L. lactis 
and L. acidophilus was modified MRS medium. The ΔOD500nm for L. lactis was from 
0.1 to 0.4. The ΔOD500nm for L. acidophilus was from 0.15 to 0.35. Therefore, we 
confirmed that both bacteria can grow on HMOs to some extent although slightly 
different growth conditions (basic medium, concentrations of HMO fractions, 
wavelength used for spectrophotometer) have been used. More relevant in 
comparison of the growth studies is the fact that Marcobal et al. (2010) used the 
whole HMO fraction whereas in our study, the HMOs were separated into the neutral 
and acidic Lewis specific fractions, or single HMO standard. The substrates were 
investigated individually. There are also some studies on the growth of Lactobacillus 
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on some other specific oligosaccharides, which can also be compared to the results 
from HMOs. Kaplan and Hutkins (2000) investigated the metabolism of Fructo- 
oligosaccharides with several Lactobacilli, such as Lactobacillus bulgaricus, 
Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus lactis and 
Lactobacillus casei using MRS-FOS agar medium or broth, and found that L. 
acidophilus could grow on MRS-FOS medium with the OD625nm about 1.6, L. 
plantarum could also grow on MRS-FOS. The results indicated that L. acidophilus is a 
FOS fermenter. Al-Tamimi et al. (2006) investigated the fermentation of arabino 
-oligosaccharides by gut bacteria and found that Lactobacilli could change the amount 
of arabinose slightly and changed arabinan and FOS significantly. Barrangou et al. 
(2003) showed that L. acidophilus could utilize fructo-oligosaccharide and described 
the gene locus involved in transport and catabolism of FOS compound. These studies 
showed that L. acidophilus could metabolize some oligosaccharides, like FOS. 
Although the structures of FOS, arabino -oligosaccharides have no structural 
similarities with HMOs, they support growth of L. acidophilus. In our study, we found 
that L. acidophilus could grow on glucose, galactose, lactose and some components 
of HMOs.  
Since Bifidobacterium species are considered as very important infant intestinal 
microorganisms, there were many studies on B. infantis and other Bifidobacterium 
species. Ward et al. (2006) compared the growth of B. infantis and L. gasseri on 
HMOs as a sole carbon substrate, and found that B. infantis could grow vigorously but 
L. gasseri grew poorly. The research group then investigated several Bifidobacteria 
species, B. infantis, B. longum, B. breve, B. bifidum and B. adolescentis (Ward et al., 
2007). The results indicated growth capabilities on HMOs; B. infantis grew well on 
HMOs as a sole carbon source, B. bifidum also grew on HMOs, B. longum and B. 
breve could grow only a little bit on HMOs, B. adolescentis did not grow on HMOs. 
LoCascio et al. (2007) did several studies on the consumption of HMOs. They found 
that B. infantis preferentially consumes small mass oligosaccharides (DP<7), and 
grew very well on HMOs with consumption of nearly all available substrates. But other 
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Bifidobacteria, such as B. longum, B. adolescentis, B. breve and B. bifidum, showed 
low or only moderate growth ability on HMOs (LoCascio et al., 2009). In 2010, they 
used comparative genomic hybridizations (CGH) and determined that HMO utilization 
gene regions are highly conserved across all B. infantis bacteria capable of growth on 
HMOs and have been changed in B. longum that can’t grow on HMOs (LoCascio et 
al., 2010). These studies are in agreement with the result from our study that found 
that B. infantis metabolized all kinds of HMO fractions and grow well, but B. longum 
could only metabolize some sorts of HMO fractions and grew not as well as B. infantis. 
Similarly, Marcobal et al. (2010) also found that the best growth occurred with B. 
infantis (ΔOD600nm of 0.52 on HMOs), compared to the other bacteria in the study. The 
ΔOD500nm in our study (between 0.1 and 0.4) was also higher than that of most other 
bacteria. The difference of OD values can be explained by different growth condition, 
concentration of HMOs and testing wavelength. Asakuma et al. (2011) studied the 
consumption of human milk oligosaccharides by B. infantis, B. longum, B. bifidum and 
B. breve. This was the first published study that reveals consumption of each single 
HMO during growth. The growth curves showed difference to our study in the time 
needed to reach the highest OD by B. infantis. The faster growth of B. infantis in the 
study of Asakuma et al. (2011) may be due to a higher concentration of HMO fractions 
used and the medium difference. The analysis of substrate consumption by B. infantis 
and B. longum were similar in both studies showing that B. infantis degraded all the 
single HMO fractions tested, and for B. longum, the degradation of the HMO fractions 
only occurred to some extent. As Bifidobacteria are unique microorganism particularly 
for the newborn infant, there are also many studies on the growth of Bifidobacteria on 
other oligosaccharides, such as FOS or GOS. In the study of Kaplan and Hutkins 
(2000), several species of Bifidobacteria were analyzed. With FOS as growth 
substrate, they found that B. adolescentis (OD625nm of 1.3), B. breve (OD625nm of 1.7), 
B. infantis (OD625nm of 1.8), and B. longum (OD625nm of 1.4) grew well whereas B. 
bifidum could not grow well on FOS. The results fit our study that B. infantis grew 
better on glucose, galactose, lactose and HMOs than B. longum. Al-Tamimi et al. 
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(2006) found that arabinan, arabinose and FOS could support the growth of 
Bifidobacteria.  Vernazza et al. (2006) compared the carbohydrate preference of five 
Bifidobacteria species using several kinds of carbohydrates. B. adolescentis was not 
able to utilize xylo-oligosaccharide (XOS), lactitol or maltodextrin; B. infantis exhibited 
some growth on all of the substrates; B. lactis could not utilize lactitol or 
high-molecular weight inulin; one B. longum could not ferment low molecular weight 
inulin or HP, maltodextrin or lactitol. Another B. longum could ferment even small 
concentrations of these substrates. Although the carbohydrates in the study of 
Al-Tamimi et al. (2006) were different to our study, their results indicated good growth 
of B. infantis on many kinds of carbon substrate, an observation we also found withB. 
infantis growing best on almost all substrates including HMOs. Amaretti et al. (2007) 
investigated the kinetics and metabolism of B. adolescentis growing on glucose, 
galactose, lactose, and Galacto-oligosaccharides (GOS), and found that B. 
adolescentis could metabolize galactose best, followed by lactose and GOS. Gopal et 
al. (2001) studied two kinds of lactic acid bacteria, Bifidobacterium lactis and 
Lactobacillus rhamnosus, they found that B. lactis could utilize GOS as selective 
substrates.  
B. vulgatus is also common gut-related microorganism. Rotimi and Duerden 
(1981) investigated the Bacteroides species in the normal neonatal faecal flora. They 
isolated 144 Bacteroides and found that B. vulgatus (46%) and B. thetaiotaomicron 
(30%) were the predominant species. All the 66 isolates of B. vulgatus fermented 
glucose, lactose, sucrose, rhamnose and xylose. As a typical species of Bacteroides, 
B. vulgatus were also studied further. In the study of Marcobal et al. (2010), very good 
growth of B. vulgatus was determined (ΔOD600nm of 0.66) on whole HMO fractions. 
Only Bacteroides fragilis was able to grow even better then B. vulgatus on HMOs. The 
ΔOD500nm of B. vulgatus in our study was from 0.1 to 0.42, which was also almost the 
maximum value compared to other bacteria. In another study from Marobal et al. 
(2011), they investigated several kinds of Bacteroides occurring in the infant gut and 
found that all the five kinds of Bacteroides species, B. fragilis, B. caccae, B. vulgatus, 
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B. ovatus and B. stericoris grew in the presence of HMOs. The growth of B. fragilis, B. 
vulgatus and B. caccae were similarly well with the OD600nm higher than 0.9. The 
OD500nm in our study was from 0.64 to 0.87, which was also with high value. The 
differences between our study and the former study were the growth condition 
(medium and concentration of HMOs) and the used wavelength. From the data of 
these studies, we conclude that B. vulgatus grows very well on HMOs.  
C. sakazakii is an opportunistic pathogen mainly associated with infections in 
neonates, outbreaks of a rare form of infant meningitis, necrotizing enterocolitis (NEC), 
bacteraemia and neonate deaths (Baumgartner et al., 2009; Iversen and Forsythe, 
2004). To proof the hypothesis that HMOs have prebiotic effects that can support the 
growth of beneficial bacteria and inhibit undesired microorganisms, we investigated 
the effect of HMOs as well as of glucose, galactose and lactose on the growth of C. 
sakazakii on. In a previous study, Joseph et al. (2013) focused on the sialic acid 
utilization by C. sakazakii, and found that C. sakazakii was the only Cronobacter 
species that was able to use sialic acid as a carbon source for growth. In our study, 
we didn’t use sialic acid; however our results indicated that C.sakazakii could grow on 
some of HMO fractions, mainly neutral fractions. C. sakazakii didn’t show growth on 
6’-SL. The reason may be that C. sakazakii doesn’t contain the enzyme which can 
hydrolyze 6’-SL into sialic acid and lactose. This comparison indicates that C. 
sakazakii seems to prefer simple sialic acid compared to sialylated HMOs. Growth 
tests of C. sakazakii on other HMO fractions of our study showed poor growth. This 
may indicate that HMOs support growth of beneficial bacteria much stronger than 
those of potentially pathogenic bacteria.  
A. muciniphila is a human intestinal mucin-degrading bacterium; it can be 
isolated from faeces in anaerobic medium containing gastric mucin as the sole carbon. 
Mucins are composed of a peptide core rich in serine and threonine residues that is 
decorated via O- or N-glycosidic bonds by oligosaccharides, which are composed of 
one or some of four primary sugars (N-acetylglucosamine, N-acetylgalactosamine, 
galactose and fucose) and are terminated by sialic acids or sulfate groups. Mucus can 
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serve as a barrier to protect the underlying epithelium from the attachment of 
pathogens and also as a source of nutrients for commensal bacteria. Previous studies 
with A. muciniphila found that it could grow on a limited number of sugars, including 
N-acetylglucosamin, N-acetylgalactosamin and glucose, but only when a protein 
source was provided (Derrien et al., 2004). There are also some studies on A. 
muciniphila and their effects on glucose homeostasis, and on intestinal epithelium in 
diet-induced obesity (Everard et al., 2013; Shin et al., 2014). But there are no 
researches on the effect of HMOs on the growth of A. muciniphila. Due to the 
importance of A. muciniphila and the structure relationship between mucin and 
oligosaccharides, we studied on the growth of A. muciniphila using glucose, galactose, 
lactose and HMO fractions. We selected the Modified Reinforced Clostridial Broth as 
the growth medium, and found that it grew well on glucose, lactose, most neutral 
HMO fractions, LNT and LNnT. 
 
5.4 Analysis of substrates in the medium before and after 
cultivations 
From the analysis of substrates in the medium before and after cultivations from 
B. infantis and B. longum, the following conclusion can be drawn: B. infantis could 
metabolize almost all the carbon substrates, including mono-, di-saccharides, neutral 
and acidic HMO fractions, and single HMO standards. B. longum could only 
metabolize part of the HMO fractions, or metabolized the components to some extent. 
The results showed that the HMOs had beneficial effects on B. infantis, but not on B. 
longum. This observation indicates a prebiotic effect of HMOs on B. infantis but not on 
B. longum. An explanation could be that B. infantis contains more suitable enzymes to 
hydrolyze HMO fractions. This can also explain the phenomenon that B. infantis is 
dominant in infants, whereas B. longum exist later in the adulthood as well. 
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5.5 Analysis of metabolic products of cultivation 
From the analysis of metabolic products after cultivation of B. infantis and B. 
longum, the following conclusion can be drawn: both microorganisms metabolize the 
carbon substrates and mainly produce lactic acid, acetic acid and some formic acid. 
The amounts of metabolic products from B. infantis were mostly larger than those 
from B. longum. This result fits the growth curves and the analysis of carbon 
substrates of the two microorganisms. Again the difference metabolic products can be 
explained by different set of enzymes to hydrolyze the HMO fractions in the two 
microorganisms. The results can also well explain the beneficial effects of HMOs on B. 
infantis.  
There were also some former studies on the fermentation of Bifidobacteria.  
Early in 1968, de Vries and Stouthamer studied on the fermentation of glucose, 
lactose, galactose, mannitol, and xylose by Bifidobacteria, and proved that acetate, 
lactate, ethyl alcohol, and formate were the main fermentation products. Recently, 
Rossi et al. (2005) studied on the fermentation of FOS by Bifidobacteria and found 
that lactic and acetic acids were the major products of FOS fermentation. Pokusaeva 
et al. (2011) concluded the carbohydrate metabolism in Bifidobacteria and 
demonstrated that Bifidobacteria produce lactic acid as one of their main fermentation 
end products, so that they were often included in the lactic acid bacteria. Kajiwara et 
al. (2002) researched on the effect of GOS, FOS and honey on the growth of five 
human intestinal Bifidobacterium spp., including B. longum and B. infantis. They also 
analyzed the fermentation products of lactic and acetic acid by HPLC. These results 
of fermentation products fit to our study in which we also found that lactic acid and 
acetic acid are the main products, and formic acid is also one of the products. 
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6. Summary 
Human milk oligosaccharides (HMOs), as the third largest components in human 
milk, are thought to be important for the development of infants for various reasons. 
Previous in vitro studies support the idea that HMOs help to build up the human gut 
microbiota in infants. It has been shown that some of the intestinal microorganisms 
found in feces of infants grow on single HMOs as sole carbon substrate. However, so 
far, the growth effect of specific HMO fractions whose pattern is strongly influenced by 
the mothers Lewis blood group and secretor status on gut bacteria has not been 
investigated yet. 
In this study, HMO fractions were isolated from human milk samples with known 
Lewis blood group specificity (Lewis a, Lewis b and Lewis negative). Human milk was 
first delipidated and deproteinized followed by an exclusion of lactose by Sephadex 
G25 Chromatography. The separation of HMO fractions into neutral (n) and acidic (a) 
fractions was achieved by FPLC-anion exchange chromatography. Resulting fractions 
and, in addition, single HMO standards as well as glucose, galactose and lactose 
were used for growth study of microorganisms.  
The HMO composition of the samples and the Lewis specificity were analyzed by 
HPAEC-PAD in combination with MALDI-TOF-MS. Fourteen fractions with Lewis a-, 
Lewis b- or Lewis-negative specificity and five single HMOs (2’-FL, 3-FL, LNT, LNnT 
and 6’-SL) were tested for their properties to function as growth substrate. According 
to previous studies and the existence of intestinal microorganisms in infants’ gut, we 
selected seven kinds of intestinal microorganisms for the study: Lactococcus lactis 
subsp. lactis, Lactobacillus acidophilus, Bifidobacterium longum subsp. infantis, 
Bifidobacterium longum subsp. longum, Bacteroides vulgatus, Cronobacter sakazakii 
and Akkermansia muciniphila. The growth studies were performed under anoxic 
condition using specific medium with 1 mM carbon substrates instead of glucose. 
Growth curves were measured by OD500nm value using spectrophotometer. The 
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carbon substrates in the medium were analyzed by RP-HPLC and the metabolic 
products (fatty acids) were analyzed by HPLC.  
From growth studies of L. lactis and L. acidophilus on glucose, galactose and 
lactose, we found that L. acidophilus grew on glucose, galactose and lactose; L. lactis 
grew on glucose, low concentration of galactose or lactose. From growth studies of 
seven microorganisms on 1 mM glucose, galactose, lactose, neutral or acidic HMO 
fractions and single HMO standards, we found that L. lactis grew well on lactose and 
on Lewis fractions LeA1n, LeA3n, LeA3a, LeB2n as well as on 3-FL, LNT and 6’-SL; L. 
acidophilus grew well on lactose, LeA1n, LeA2n, LeA3n, LeB1n, LeB2n, LeA1a, 
LeB2a, single 2’-FL, 3-FL and 6’-SL; B. infantis grew well on most of the carbon 
substrates, B. longum could only grow well on some of the substrates. B. vulgatus 
grew well on lactose, LeA1n, LeA2n, LeB1n, LeB2n, LeB2n, Le0n, Le0a, 2’-FL, LNT 
and LNnT. C. sakazakii could grow on glucose, lactose and 3-FL, but most carbon 
substrates seem to have no effect nor inhibitory effect on the growth. A. muciniphila 
grew well on glucose, lactose, LeA2n, LeA3n, LeB1n, LeB2n, Le0n, LNT and LNnT. 
Most neutral HMO fractions had better growth effects than acidic HMO fractions on 
bacterial growth. 
In order to analyze the carbon substrates before and after cultivation, 2-AA was 
used for labeling and RP-HPLC was used for quantification. From the analysis of 
substrates, we found that B. infantis could metabolize almost all the carbon substrates, 
including mono-, di-saccharides, HMO fractions, and single HMO standards. B. 
longum could only metabolize some kinds of the HMO fractions, or metabolized some 
components to some extent.  
From the analysis of metabolic products using HPLC (analysis for fatty acid 
detection), we found that both B. infantis and B. longum consumed the carbon 
substrates, including mono-, di-saccharides, HMO fractions and single HMOs; they 
mainly produced lactic acid, acetic acid and some formic acid. The amounts of fatty 
acids produced by B. infantis were mostly larger than those from B. longum. 
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In conclusion, HMOs can positively affect the growth of intestinal microorganisms. 
B. infantis and B. vulgatus grew well on almost all the HMO fractions. B. longum, L. 
lactis, L. acidophilus grew well on some of HMO fractions. C. sakazakii could grow on 
only a few carbon substrates whereas single HMOs and Lewis specific fractions seem 
to have no effect. A. muciniphila grew well on most of the neutral HMO fractions. The 
results indicated that most neutral HMO fractions had better growth effects than acidic 
HMO fractions on bacterial growth. In addition, there were no distinct differences 
between the effects of the various Lewis blood group specific neutral HMO fractions. 
   
 
 
 
 
 
 
 
 
 
Zusammenfassung 
 
114 
 
7. ZUSAMMENFASSUNG 
Aus verschiedenen Gründen wird angenommen, dass humane 
Milcholigosaccharide (HMOs), die am dritthäufigsten in der Milch vertretenen 
Komponenten, bei der Entwicklung des Säuglings eine wichtige Rolle spielen. 
Frühere Studien belegen, dass HMOs am Aufbau der Darmmikrobiota des Säuglings 
beteiligt sind. In Zellkulturstudien konnte gezeigt werden, dass einige der intestinalen 
Mikroorganismen, die in Säuglingsfaeces vorkommen, bei Zugabe von bestimmten 
HMOs als einzigem Kohlenstoff (C)-Substrat wachsen. Bisher wurde jedoch die 
Auswirkung spezifischer HMO-Fraktionen, deren Muster stark durch die 
Lewis-Blutgruppe und den Sekretorstatus der Mutter beeinflusst wird, noch nicht auf 
das Wachstum von Darmbakterien hin untersucht. 
In der vorliegenden Studie wurden HMO-Fraktionen aus Humanmilchproben mit 
bekannter Lewis-Blutgruppen-Spezifität (Lewis a, Lewis b und Lewis negativ) isoliert. 
Nachdem die Milch zunächst entfettet und entproteinisiert worden war, wurde 
anschließend mittels Sephadex G25 Chromatographie die Lactose entfernt. Mittels 
FPLC-Anionenaustauschchromatographie wurden die HMO-Fraktionen in neutrale 
und saure Fraktionen getrennt. Die so entstandenen Fraktionen, einzelne 
HMO-Standards sowie Glucose, Galactose und Lactose wurden für die Untersuchung 
des Wachstums der Mikroorganismen benutzt. 
Die HMO-Zusammensetzung der Proben und die Lewis-Spezifität wurden mittels 
HPAEC-PAD in Kombination mit MALDI-TOF-MS analysiert. Vierzehn Fraktionen mit 
Lewis a-, Lewis b- oder Lewis-negativ-Spezifität und fünf einzelne HMOs (2’-FL, 3-FL, 
LNT, LNnT und 6’-SL) wurden auf ihre Eignung als Wachstumssubstrat untersucht. 
Entsprechend früheren Studien und den im Säuglingsdarm vorhandenen 
Mikroorganismen wurden sieben intestinale Mikroorganismen für unsere Studie 
ausgewählt: Lactococcus lactis subsp. lactis, Lactobacillus acidophilus, 
Bifidobacterium longum subsp. infantis, Bifidobacterium longum subsp. longum, 
Bacteroides vulgatus, Cronobacter sakazakii und Akkermansia muciniphila. Die 
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Wachstumsstudien wurden unter Anwendung eines spezifischen Mediums mit 1 mM 
verschiedener Kohlenstoff-Substrat anstelle von Glucose unter anoxischen 
Bedingungen durchgeführt. Die Wachstumskurven wurden anhand des OD500nm 
Wertes mittels Spektrophotometer gemessen, die C-Substrate im Medium anhand 
von RP-HPLC und die metabolischen Produkte (Fettsäuren) mittels HPLC analysiert. 
Wachstumsstudien an L. lactis und L. acidophilus mit Glucose, Galactose und 
Lactose zeigten, dass L. acidophilus erwartungsgemäß mit Glucose, Galactose und 
Lactose wächst, L. lactis wuchs mit Glucose und mit geringen Konzentrationen von 
Galactose oder Lactose. Anhand von Wachstumsstudien an sieben Mikroorganismen 
mit 1 mM Glucose, Galactose, Lactose, neutralen und sauren HMO-Fraktionen und 
einzelnen HMO-Standards konnte festgestellt werden, dass L. lactis gut auf Lactose 
und auf den Lewis-Fraktionen LeA1n, LeA3n, LeA3a, LeB2n wie auch auf 3-FL, LNT 
und 6’-SL wuchs; L. acidophilus wuchs gut auf Lactose, LeA1n, LeA2n, LeA3n, LeB1n, 
LeB2n, LeA1a, LeB2a, single 2’-FL, 3-FL und 6’-SL; B. infantis zeigte auf den meisten 
C-Substraten ein gutes Wachstum, B. longum nur mit einigen der Substrate. B. 
vulgatus wuchs mit Lactose, LeA1n, LeA2n, LeB1n, LeB2n, LeB2n, Le0n, Le0a, 2’-FL, 
LNT und LNnT gut. C. sakazakii konnte mit Glucose, Lactose und 3-FL wachsen, die 
meisten C-Substrate jedoch scheinen keine Auswirkungen auf das Wachstum zu 
haben.  A. muciniphila zeigte ein gutes Wachstum auf Glucose, Lactose, LeA2n, 
LeA3n, LeB1n, LeB2n und Le0n, LNT und LNnT. 
Um Kenntnisse zur gezielten Verwertung von Kohlenstoffsubstraten durch 
einzelne Mikroorganismen zu erhalten, wurden Aliquots der jeweiligen Mono-, Di-, 
oder Oligosaccharide vor und nach der Kultivierung mittels 2-AA markiert und 
anschließend mittels RP-HPLC quantifiziert. Dabei zeigte sich, dass B. infantis 
praktisch alle Kohlenstoffsubstrate metabolisiert hat, einschliesslich Mono- und 
Di-sacchariden, HMO-Fraktionen sowie einzelnen HMO-Standards. B. longum 
dagegen metabolisierte nicht alle getesteten HMO-Fraktionen bzw. verwertete 
manche Substrate nur in geringerem Mengen.  
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Die Analyse der metabolischen Produkten, gemessen an dem Auftreten von 
Fettsäuren, ergab, dass beide Mikroorganismen die eingesetzten Monosaccharide, 
Dissaccharide, HMO-Fraktionen und einzelne Standards verwerteten. Dabei wurden 
hauptsächlich Milchsäure, Essigsäure und Ameisensäure gebildet, wobei die 
produzierten Mengen bei B. infantis deutlich größer als bei B. longum waren. 
Schlussfolgernd kann festgestellt werden, dass HMOs das Wachstum intestinaler 
Mikroorganismen positiv beeinflussen können. B. infantis und B. vulgatus zeigten mit 
fast allen HMO-Fraktionen ein gutes Wachstum, B. longum, L. lactis, L. acidophilus 
auf einigen. C. sakazakii konnte nur auf wenigen Kohlenstoff-Substraten wachsen, 
während einzelne HMOs und Lewis-spezifische Fraktionen keine Auswirkungen zu 
haben scheinen. A. muciniphila wies auf den meisten der neutralen HMO-Fraktionen 
ein gutes Wachstum auf, nicht aber auf sauren Oligosacchariden. Die Ergebnisse 
zeigten, dass die meisten neutralen HMO-Fraktionen das Wachstum der 
Mikroorganismen eher förderten als saure HMO-Fraktionen. Zwischen den 
verschiedenen Lewis-Blutgruppen-spezifischen HMO-Fraktionen gab es hinsichtlich 
der Auswirkungen keine deutlichen Unterschiede. 
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